DMID Protocol 16- [ADDRESS_77563] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77564] 10, 2017  A Phase 1 Safety and Intrapulmonary Pharmacokinetics  Study of 
ZTI-01 (Intravenous Fosfomycin Disodium) in Healthy Adult 
Subjects  
DMID Protocol Number:  16-0058  
DMID Funding Mechanism: Vaccine and Treatment Evaluation Unit  
Pharmaceutical Support Provided by: [CONTACT_71478], Inc.  
IND Sponsor: NIH/NIAID/DMID  
Principal Investigator s: Emmanuel B. Walter, MD, MPH and Loretta G. Que, MD  
DMID Clinical Project Manager : Maureen Mehigan, RN  
DMID Medical Officer s: Varduhi Ghazaryan, MD, MPH   
DMID Medical Monitor:  Tatiana Beresnev , MD  
Version Number: 9. [ADDRESS_77565] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77566] 10, 2017  STATEMENT OF COMPLIA NCE  
The trial  will be carried out in accordance with Good Clinical Practice (GCP)  and as required by:  
• [LOCATION_002] (US) 45 Code of Federal Regulations (CFR) Part 46 : Protection of Human Subjects  
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50 (Protection of 
Human Subjects) , 21 CFR Part 54 (Financial Disclosure by [CONTACT_6230]) , 21 CFR Part 56  
(Institutional Review Boards) , and 21 CFR Part 11, 21 CFR Part 312 (Investigational New Drug 
Application ). 
• International Conference on Harmoni zation ( ICH) E6:GCP; 62 Federal Register [ZIP_CODE] (1997); and 
future revisions  
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, 
Repo rt of the National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research, Research Involving Human Subjects, as applicable  
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , as applicable  
• Applicable Federal, State, and Local Regulations and Guidance  
  
DMID Protocol 16- [ADDRESS_77567] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77568] 10, 2017  SIGNATURE [CONTACT_71514] e trial will be conducted according to all 
stipulations of the protocol, including all statements regarding confidentiality, and according to local legal 
and regulatory requirements and applicable US federal regulations and ICH E6 : GCP  guidelines.  
I agree to conduct the s tudy in compliance with GCP and applicable regulatory requirements.  
I agree to conduct the study in accordance with the current protocol and will not make changes to the protocol without obtaining the S ponsor’s approval and I nstitutional Review Board ( IRB)/Independent 
Ethics Committee ( IEC) approval, except when necessary to protect the safety, rights, or welfare of 
subjects.  
 
Site Investigator  Signature : 
 
[INVESTIGATOR_14586]:   Date:   
 Emmanuel B. Walter, MD, MPH  
Professor of Pediatrics, Duke University  
   
Site Investigator  Signature : 
 
[INVESTIGATOR_14586]:   Date:   
  Loretta G. Que, MD  
Professor of Medicine, Duke University    
  
DMID Protocol 16- [ADDRESS_77569] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77570] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77571] Replacement  ...................................................................................................................... 38 
5.3.5.  Termination of Study  ..................................................................................................................... 38 
6. Study Intervention/Investigational Product  ................................................................................... [ADDRESS_77572] Compliance with Study Drug  ................................................................... 42 
6.6. Concomitant Medicat ions/Treatments  ........................................................................................... 42 
7. Study Schedule  .............................................................................................................................. 43 
7.1. Screening (Day - 30 to Day -1) ....................................................................................................... 43 
7.2. Enrollment/Baseline (Day - 1 to Day 1)  ......................................................................................... 43 
7.3. Day 1 to Day 2  ............................................................................................................................... 44 
7.4. Day 2 (Day of Discharge from DEPRU)  ....................................................................................... 45 
7.5. Day 3 (Telephone Follow -up Call)  ................................................................................................ 45 
7.6. Early Termination Visit  ................................................................................................................. 45 
7.7. Unscheduled Visit (if needed)  ....................................................................................................... 46 
8. Study Procedures/Evaluations  ....................................................................................................... [ADDRESS_77573] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77574] 10, 2017  8.2.1.  Clinical Laboratory Evaluations  .................................................................................................... 47 
8.2.2.  Bronchoscopy and Bronchoalveolar Lavage (BAL)  ...................................................................... [ADDRESS_77575] Values or Abnormal 
Clinical Findings  ......................................................................................................................................... 54 
9.3. Reporting Procedures  ..................................................................................................................... 54 
9.3.1.  Serious Adverse Events  ................................................................................................................. 55 
9.3.2.  Regulatory Report ing for Studies Conducted Under DMID -Sponsored IND  ............................... 55 
9.3.3.  Reporting of Pregnancy  ................................................................................................................. 56 
9.4. Type and Duration of Follow -up of Subjects after Adverse Events  .............................................. 56 
9.5. Halting Rules  ................................................................................................................................. 56 
9.6. Safety Oversight  ............................................................................................................................ 56 
9.6.1.  Independent Safety Monitor (ISM)  ................................................................................................ 57 
9.6.2.  Safety Monitoring Committee (SMC)  ........................................................................................... [ADDRESS_77576] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77577] 10, 2017  11.3.  Final Analysis Plan  ........................................................................................................................ 60 
12. Source Documents and Access to Source Data/Documents  .......................................................... 63 
13. Quality Control and Quality Assurance  ......................................................................................... 64 
14. Ethics/Protection of Human Subjects  ............................................................................................ [ADDRESS_77578]  ............................................................................................................ 65 
14.3.  Informed Consent Process  ............................................................................................................. 65 
14.4.  Exclusion of Women, Minorities, and Children (Special Populations)  ......................................... [ADDRESS_77579] Keepi[INVESTIGATOR_007]  .............................................................................................. 69 
15.1.  Data Management Responsibilities  ................................................................................................ 69 
15.2.  Data Capture Methods  ................................................................................................................... 69 
15.3.  Types of Data  ................................................................................................................................. 69 
15.4.  Timing/Reports  .............................................................................................................................. 70 
15.5.  Study Records Retention ................................................................................................................ 70 
15.6.  Protocol Deviations  ........................................................................................................................ 70 
16. Publication Policy  .......................................................................................................................... 71 
17. Literature References ..................................................................................................................... 72 
18. Supplements/Appendices  ............................................................................................................... 76 
Appendix A: Schedule of Study Procedures And Evaluations  ................................................................... 76 
Appendix B : Adverse event toxicity grading scale  ..................................................................................... 79 
Appendix C : Venipuncture schedule and volumes ..................................................................................... [ADDRESS_77580] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77581] OF TABLES  
Table 1: Study drug administration ................................................................................................17  
Table 2: Bronchoscopy with BAL sampling times  ........................................................................17  
Table 3: Blood PK sampling times  ................................................................................................17  
Table 4: AEs occurring in ≥2% of patients receiving ZTI -01 in a phase 2/3 clinical trial  ............26  
Table 5: ZTI -01 dose prepara tion guidelines  .................................................................................40  
Table 6: ZTI -01 (disodium fosfomycin) reconstitution with WFI .................................................41  
Table 7: Pharmacokinetics sampling times ....................................................................................49  
Table 8: Probability of observing at least one event for a r ange of true event rates based 
on a sample size of n=30 subjects ...............................................................................60  
Table 9: Schedule of study procedures and evaluations  ................................................................76  
Table 1 0: Clinical adverse event definition and grading scale  ......................................................80  
Table 1 1: Laboratory adverse event definition and grading scale  .................................................85  
Table 1 2: Venipuncture schedule and volumes  .............................................................................[ADDRESS_77582] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77583] OF FIGURES  
Figure 1: Schematic of Study Design  ............................................................................................[ADDRESS_77584] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77585] OF ABBREVIATION S 
AE Adverse Event/Adverse Experience  
ALT   Alanine Aminotransferase  
AM Alveolar Macrophage  
ALP  Alkaline Phosphatase  
AST  Aspartate Aminotransferase  
AUC  Area under the concentration -time curve  
AUC 0-t AUC calculated to the last measured concentration  
AUC 0-inf AUC extrapolated to infinity  
BAL  Bronchoalveolar lavage  
BMI  Body Mass Index  
Cmax Maximum Measured Concentration  
CRF  Case Report Form  
CDC  Centers for Disease Control and Prevention  
CFR  Code of Federal Regulations  
CFU  Colony Forming Unit  
CL Clearance  
CrCl  Creatinine Clearance  
CRE  Carbapenem -Resistant Enterobacteriaceae  
CROMS  Clinical Research Operations and Management Support  
DCC  Data Coordinating Center  
DEPRU  Duke Early Phase Research Unit  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiolo gy and Infectious Diseases  
DMID Protocol 16- [ADDRESS_77586] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77587] 10, 2017  DMID -CMS  DMID Clinical Materials Services (CMS, Fisher BioServices)  
ECG  Electrocardiograph  
ELF Epi[INVESTIGATOR_71442] -Spectrum Beta -Lactamase  
FDA  Food and Drug Administration  
FSH Follicle -Stimulating Hormone  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GI Gastrointestinal  
HBsAg  Hepatitis B Surface Antigen  
HCV  Hepatitis C Virus  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
ICMJE  International Committee of Medical Journal Editors  
IM Intramuscular  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
IV Intravenous  
LC-MS/MS  Liquid chromatography -mass spectrometry/mass spectrometry  
MIC  Minimum Inhibitory Concentration  
MOP  Manual of Procedures  
MDR  Multi -Drug Resistant  
MRSA  Methicillin Resistant S. aureus  
DMID Protocol 16- [ADDRESS_77588] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77589] 10, 2017  N Number (typi[INVESTIGATOR_19737])  
NCI National Cancer Institute  
NDA  New Drug Application  
NEJM  New England Journal of Medicine  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
OCRA  Office of Clinical Research Affairs  
OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
ORA  Office of Regulatory Affairs  
PD Pharmacodynamics  
PHI Protected Health Information  
PI [INVESTIGATOR_71443]-TAZ  Pi[INVESTIGATOR_049] -Tazobactam  
PK Pharmacokinetics  
PRSP  Penicillin Resistant S. pneumonia  
PST Product Support Team  
QA Quality Assurance  
QC Quality Control  
RIC Resistance Inhibitory Concentration  
RLD  Reference Listed Drug  
SAE  Serious Adverse Event/Serious Adverse Experience  
SMC  Safety Monitoring Committee  
SOP Standard Operating Procedure  
T½ Terminal Elimination Half -Life 
DMID Protocol 16- [ADDRESS_77590] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77591] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77592] 10, 2017  PROTOCOL SUMMARY  
Title:  
A Phase 1 S afety  and Intrapulmonary Pharmacokinetic s Study of ZTI -
01 (Intravenous Fosfomycin Disodium) in Healthy Adult Subjects  
Phase:  1 
Population:  
40 healthy male and female adults will be enrolled  and randomized (to 
obtain 30 evaluable subjects)  aged  18-45 years , inclusive , with BMI 
18-30 kg/m2, inclusive, and body weight >50 kg (110 lbs)  
Number of Sites:  
1 (Duke Early Phase Research Unit [DEPRU] , Durham, NC)  
Study Duration:  
Approximately [ADDRESS_77593] Participation Duration:  
Individual subject participation will be approximately 33 days to 
include up to 30 days between screening and baseline /enrollment , 2 
days treatment (dosing)  and [ADDRESS_77594] -dosing  follow -up 
Description of Agent or 
Intervention:   
ZTI-01 [intravenous (IV) fosfomycin disodium ] packed in  a single  
Type 1 glass  vial equivalent to 4 g of fosfomycin and 1.28 g of sodium 
with inactive ingredient  of recrystallized succinic acid.  
Objectives : 
Safety:  
• Determine the safety of multiple doses of ZTI -01 (6 g  dose 
administered as a 1 -hour IV  infusion  (+10 minute window) , every 
8 hours, for a total of 18 g in three doses)  
Pharmacokinetic:  
• Determine the plasma and intrapulmonary pharmacokinetics (PK) 
(epi[INVESTIGATOR_71444], and alveolar macrophage concentrations of 
fosfomycin) after multiple doses of ZTI -01 ([ADDRESS_77595] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77596] 10, 2017  as a 1 -hour IV infusion  (+10 minute window),  every 8 hours, for a 
total of 18 g in three doses)  
Outcome Measures:  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
  
Description of Study Design:  Safety:  
• The occurrence of adverse events ( AEs) , summary of physical 
exam findings, vital signs, clinical laboratory tests, and ECGs ( B) 
at any time from the start of study drug administration through the 
end of subject  follow -up 
Pharmacokinetic : 
• Plasma ZTI -01 concentrations will be measured by a validat ed LC-
MS/MS assay  for the blood samples collected during the study 
(Table 3 ). PK parameters of ZTI -01 will be estimated  from the 
plasma concentration including  maximum measured plasma 
concentration (C max), area under the concentration v s. time curve 
(AUC 0-8), time to peak concentration (t max), terminal elimination 
half-life (t 1/2), terminal -phase elimination rate constant ( λz), 
volume of distribution (Vd), and clearance (CL) . 
• Intrapulmonary PK of ZTI -01 defined as percent penetration of 
lung epi[INVESTIGATOR_71444] (ELF) and alveolar macrophages 
(AMs).  The ratios of ELF and AM concentrations of fosfomycin to 
simultaneous pla sma concentrations will be calculated for each 
subject and summarized for each sampling time. The median concentrations of fosfomycin from the BAL sampling times will be used to estimate the AUC
0-[ADDRESS_77597] of 18 g of ZTI -01 in three 
divided doses (Table 1 ). A total of 30 enrolled subjects will be 
randomized to undergo  a single standardized bronchoscopy with 
bronchoalveolar lavage (BAL) at one of five  sampling times as defined 
below  (Table 2 ). A total of [ADDRESS_77598] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77599] dose (Da y -
1) for pre -dosing assessments. The Treatment Phase will start on the 
day of first dose  (Day 1 ) and end at the time of discharge from 
DEPRU . Three IV doses of ZTI -01 will be administered every 8 hours 
(hours 0, 8, and 16 during the Treatment Phase). B lood samples for PK 
measurements will be collected before each dose, up to [ADDRESS_77600] IV  infusion ( Tables 2  and 3). One bronchoscopy with 
BAL will be completed on each subject at the timepoint to which that 
subject was randomized. Key electrolytes will be remeasured prior to 
each subject’s bronchoscopy in order to minimize risk of arrhythmia. Subjects will be discharged following the final 12- hour blood sampling 
time point (if safety parameters are acceptable to the Investigator). Safety assessments will be conducted during the entire 24- hour 
Treatment Phase. The Follow -Up Phase consists of a t elephone 
interview on Day 3 for symptom -driven safety assessments.  
 
Estimated Time to Complete Enrollment:   
Approximately [ADDRESS_77601] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77602] 10, 2017  Table 1 : Study d rug administration  
Study drug  Formulation/Strength  Each dose/Route  Dosing interval  Total no.  of doses 
ZTI-01 Fosfomycin, disodium 
salt, 4 g fosfomycin per 
vial 6 g fosfomycin per 
200 mL dose, 
1-hour IV infusion 
(+10 minute 
window)  Every 8 hours  3 
 
Table 2 : Bronchoscopy with BAL sampling t imes  
 BAL sampling times  after start of third IV infusion  of ZTI -01* 
30 minutes  1 hour  15 minutes  2 hours  5 hours  8 hours  
No. s ubjects (n=30 
completed)  6 6 6 6 6 
*Each subject will complete a single standardized bronchoscopy with BAL randomized to one of the five 
sampling times shown.   
 
 Table 3 : Blood PK s ampling t imes  
 
  Dosing  Dose 1  Dose 2  Dose 3  
Pre-Dose  During/After Dose  Pre-Dose  Pre-Dose  During/After Dose  
Timing of PK 
blood sample  Within [ADDRESS_77603] (last) dose  
DMID Protocol 16- [ADDRESS_77604] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77605] 10, 2017  Figure 1 : Schematic of Study Design  
 

DMID Protocol 16- [ADDRESS_77606] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77607] 10, 2017  1. KEY ROLES  
Individuals:  
Site Principal Investigator:  
[INVESTIGATOR_71445]:   
Emmanuel B. Walter, MD, MPH and Loretta G. Que, MD  
 
Maureen Mehigan, RN  
Bacteriology and Mycology Branch  
DMID/NIAID/NIH/HHS  
[ADDRESS_77608]/Rm7E19 
Bethesda, MD [ZIP_CODE]  Phone:240- 627-3317 
[EMAIL_1390]  
DMID Medical Officer   Varduhi Ghazaryan, MD, MPH  
DMID Medical Monitor  Tatiana Beresnev , MD , MSHS  
Institutions:  Duke Vaccine and Trials Unit (DVTU)  
[ADDRESS_77609]  
Durham, NC [ZIP_CODE] 
Emmanuel Walter, MD, MPH  
[PHONE_1726] 
[EMAIL_1391]  
 
Duke Early Phase Research Unit  
[ADDRESS_77610]  
Durham, NC [ZIP_CODE] 
Jeff Guptill, MD, MA, MHS  
[PHONE_1727] 
DMID Protocol 16- [ADDRESS_77611] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77612] 10, 2017  [EMAIL_1392]  
 
Duke Investigational Drug Service  
[ADDRESS_77613], Duke Clinic  
Durham, NC [ZIP_CODE] 
Safety and Pharmacovigilance 
Contractor:  
 DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_77614]., Suite 650  
Bethesda, MD [ZIP_CODE]  
SAE Hot Line: 1 -[PHONE_889] (US)  
SAE Fax: 800- 275-7619 (US)  
SAE Email: [EMAIL_1393]  
 
Data Coordinating Center:  
 The Emmes Corporation  
 [ADDRESS_77615]., Suite 700  
 
Rockville, MD   [ZIP_CODE]  
 
Phone: 301- 251-1161 
[EMAIL_1394]  
 
 
Clinical Materials Services:  
  
DMID -CMS  
[ADDRESS_77616]  
Germantown, MD [ZIP_CODE]  
Tel: (240) 477- 1350  
Fax: (240) 477- 1360 
E-mail: [EMAIL_1395]  
DMID Protocol 16- [ADDRESS_77617] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77618] 10, 2017   
Laboratory(ies), if applicable:   
 
DUHS Clinical Laboratories  
[ADDRESS_77619] 
Durham NC, [ZIP_CODE] 
Phone: 919- 681-6335 
Fax: [ADDRESS_77620]  
Durham, NC [ZIP_CODE] 
Phone: 919- 613-[ADDRESS_77621]  
Exton, PA [ZIP_CODE]  
Phone: 610- 232-0100 
Fax: 610- 232-[ADDRESS_77622] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77623] antimicrobials has reached alarming levels in recent decades resulting in crisis 
and necessitating the need for more antibiotic treatment options, particularly among Gram -negative 
bacteria, including those that express extended- spectrum beta- lactamases (ESBL s) and the carbapenem -
resistant Enterobacteriaceae (CRE). The lack of available and effective antibiotics for these organisms has 
created an unmet medical need that is widely acknow ledged (Alemayehu et al, 2012). Infections with 
CRE are difficult to treat and there are limited treatment choices available or options suitable for certain 
patients. Mortality rates as high as 40% -50% have been associated with CRE infection , and thus the 
Centers for Disease Control and Prevention (CDC) considers this an urgent threat to public health (CDC 
Report 2013).  
Since the first report in a US hospi[INVESTIGATOR_35905] 2001, CRE prevalence in the US has increased rapi[INVESTIGATOR_71446] 6% of all hospi[INVESTIGATOR_71447] g reported at least one such infection. Data from the European 
Antimicrobial Resistance Surveillance Network (EARS -Net) showed statistical ly significan t increas es in 
the prevalence of carbapenem resistance among  K. pneumonia e isolates from  2005 to  2010 in  
progressively more countries across Europe (Magiorakos et al , 2013). Given the rapid rise of carbapenem 
resistance outside the US, it is very probable that we will see increasing rates in the US  as well . In 
particular, rising rates among long- term-care facilities, where an  estimated 25% of elderly persons  in the 
US will reside at some point in their lives , is alarming . In a cross -sectional study of facility residents seen 
in the emergency department for u rinary tract infection s (UTI s), multidrug -resistant (MDR) bacteria were 
identified in up to 80% of isolates (Genao and Buhr, 2012).  
There has been a renewed interest and effort to expedite the availability of antibiotics effective against 
these resistant pathogens. To fill the void of desperately n eeded therapeutic options, a re- evaluation of 
“forgotten,”  older antibiotics and their different formulations  has been proposed (Kanj and Khanafani, 
2011; Pulcini et al, 2012). Despi[INVESTIGATOR_71448], many of these drugs require a 
“moderni zation ” of PK -pharmacodynamics (PD) to adequately bridge clinical data and thereby [CONTACT_71479]. Evidence suggests that the development of 
resistance is associated with  the use of suboptimal dosing regimens, while optimal dosing regimens are 
associated with a higher likelihood of  suppress ing the development of resistance (Drusano, 2003). For 
this to be feasible, alternative approaches to the development of these forgotten antibiotics must be 
employ ed and used in support of marketing approval.  
ZTI-01 is fosfomycin for injection, a phosphonic acid derivative formulated as a disodium salt. 
Fosfomycin acts by [CONTACT_71480], thereby [CONTACT_71481] (Kahan et al., 1974). Uptake into the bacterial cell occurs via active transport, by [CONTACT_941] L -α-glycerophosphate transport 
DMID Protocol 16- [ADDRESS_77624] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77625] anaerobic 
pathogens and many G ram-positive and - negative bacteria, including the increasingly problematic CRE 
and ESBL- producing  organisms. Staphylococcus aureus (including MRSA) , Streptococcus pneumonia e 
(including PRSP), Escherichia coli , Neisseria meningitidis , Haemophilus influenzae , Klebsiella 
pneumoniae , Enterococcus faecalis (including VRE), Serratia marcescens, Pseudomonas aeruginosa, 
and Proteus mirabilis are among the many organisms in which fosfomycin is active (Michalopoulos et al , 
2011).  
In Europe and Japan, IV fosfomycin has provided a safe and effective option for treating patients with UTIs and a variety of other, often very severe, infections, including MDR infections in patients with  
cystic fibrosis (Mirakhur et al , 2003) and sepsis ( Matzi, 2010) for more than 45 years. ZTI -01 penetrates 
rapi[INVESTIGATOR_71449], urine, soft tissues, lung, bone, cerebrospi[INVESTIGATOR_872], and heart valves , making it a desirable antibiotic treatment option (Roussous et 
al, 2009). Falagas et al (2008) compi[INVESTIGATOR_71450], 
IV, and intramuscular  (IM)  fosfomycin for the treatment of patients with Gram -positive and/or Gram -
negative bacterial infections, excl uding UTI  and gastrointestinal (GI) infection. Of the 1311 potentially 
relevant studies, 62 studies involving  1604 patients with a variety  of infections (pneumonia and other 
respi[INVESTIGATOR_18073]; osteomyelitis; meningitis; ear, nose, and throat infections; surgical infections; 
obstetric and gynecological infections; arthritis; septicemia; peritonitis; cervical lymphadenitis; eye 
infections; diabetic foot infections; and typhoid fever ) were included. The most frequently involved 
pathogens were S. aureus  and P. aeruginosa, and fosfomycin was administered via oral, IV , or IM  route s 
at dosages  of 2- 24 g daily, administered in divided doses every 6- 8 hours . The mean duration of 
fosfomycin treatment ranged from 5 to 21 days, including fosfomycin adminis tered alone or in 
combination with other antibiotics. Cures were achieved in 81.2% ( 1242 /1529) of  patients, and clinical 
improvement was noted in 3.0% ( 46/1529 ) of patients .  
Among 664 patients in these studies, fosfomycin treatment was also well tolerated : 5.4% reported mild GI  
symptoms (e.g., nausea, diarrhea, epi[INVESTIGATOR_44443], vomiting); 4.0% developed skin manifestations (e.g., rash, dermatitis, exanthema); 3.0% experienced pain at the injection site or phlebitis; and 2.1%, 1.2%, and 0.1% showed moderate increases in platelet count, eosinophil count, and transaminase level, respectively.  
In general, fosfomycin shows little toxicity, and adverse effects are generally mild following parenteral doses up to 24 g/day. Renal impairment significantly dec reases the excretion of fosfomycin and doses 
should be reduced if the creatinine clearance is less than 50 ml/min. Since fosfomycin shows synergistic 
action with other antimicrobials , it is often used in combination (Kastoris et al, 2010). In fact, treatme nt 
with fosfomycin is considered free from the nephrotoxicity that characterizes treatment with 
aminoglycosides. Animal studies have demonstrated that fosfomycin protect s against nephrotoxicity by 
[CONTACT_71482] -induced histamine release from mast -cell destruction. Fosfomycin also 
DMID Protocol 16- [ADDRESS_77626] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77627] cells (Walwarawooth , 2004; 
Popovic et al , 2010).  
Despi[INVESTIGATOR_71451], fosfomycin has retained excellent antimicrobial activity. The emergence of MDR 
organisms such as fluoroquinolone -resistant E . coli, ESBL -producing bacteria, and carbapenem -resistant 
K. pneumoniae  has prompted the  re-evaluation of fosfomycin, due to the dwindling number of effective 
antimicrobial options (Pulcini et al, 2012).  
ZTI-[ADDRESS_77628] (QIDP) and Fast Track designations by [CONTACT_71483] -threatening infections, including those caused 
by [CONTACT_71484] , for which limited o r no antibacterial therapy has been developed. Two 
clinical studies (DMID -13-0064 and ZEUS)  support US registration of ZTI -01. 
A Phase 1 , single -dose, randomized, three -period, crossover study (Wenzler , 2017) was conducted at a 
single center to assess the safety, tolerability, and PK of ZTI -01 (fosfomycin for injection) in healthy 
adults . Subjects were randomized to receive one  of three  treatment sequences (1 or 8 g ZTI -01 
administered as a 1 -hour IV infusion (+10 minute window)  or 3 g fosfomycin tromethamine [sachet, 
Monurol®] administered orally per label instructions). Each treatment sequence was enrolled in parallel , 
and each subject  received all three  treatments in crossover fashion. Each crossover period included a 
single dose of study drug under fasted conditions, followed by [CONTACT_71485] /urine 
collection s for PK measures up to 48 hours. Each treatment period was se parated by a 3 - to 7- day 
washout period.  
A total of 30 healthy subjects were enrolled and randomized , and 28 of them  completed all study 
procedures. The mean age was 27 years (range, 18- 44). There were no serious adverse events (SAEs) , and 
no subjects dis continued treatment due to treatment -emergent adverse event s (TEAE s).  
The incidence of TEAEs was 39.3% in the ZTI -01 IV (1- g) group, 67.9% in the ZTI -01 IV (8- g) group, 
and 43.3% in the oral Monurol group. The most common TEAEs (>2 subjects in any group) in the ZTI -01 
IV (1 -g), ZTI -01 IV (8- g), and Monurol groups were decreased heart rate (10.7, 28.3, and 16,7%), 
decreased blood calcium (17.9, 10.7, and 13.3%), and headache (10.7, 7.1, and 3.3%), respectively. None 
of the reported TEAEs was considered clin ically significant  based on clinical evaluation and course. 
Abnormal laboratory findings were mild, asymptomatic, and not considered clinically significant . The 
most common (affecting >2 subjects) laboratory abnormality was hypocalcemia. There were no clin ically 
significant  changes in vital signs in any subject during the study. The most common (affecting >2 
subjects) abnormality in vital sign measurements was a decreased heart rate. A decrease in systolic blood pressure was reported by [ADDRESS_77629] in the ZTI -01 IV (1 -g) group, considered mild in severity and related 
to study treatment by [CONTACT_737]. There were no subjects with abnormal ECG intervals.  
A Phase 2/3, multicenter, randomized, double -blind, comparative study (ZEUS, [STUDY_ID_REMOVED], 
unpublished) t o evaluate the safety and efficacy of ZTI -01 (fosfomycin disodium) v s. pi[INVESTIGATOR_049]/  
tazobactam (PIP -TAZ) in the treatment of complicated UTIs, including acute pyelonephritis (AP), in 
DMID Protocol 16- [ADDRESS_77630] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77631] 10, 2017  hospi[INVESTIGATOR_71452] . A total of 465 subjects were randomized at 72 sites in Central 
and Eastern Europe and the US. The mean age of treated patients was 50 years (range, 18- 89) across 
treatment arms , and m ost (63%) were female. About 30%  of patients had sepsis at baseline, based on 
systemic i nflammatory response syndrome (SIRS) criteria, and 9% of patients had bacteremia at baseline.  
Subjects were randomized (1:1) to receive a fixed duration of 7 to 14 days of either ZTI -01 (6 g) IV 
infused over 1 hour every 8 hours  (18 g/day) , or PIP -TAZ (4 g  pi[INVESTIGATOR_049]/0.5 g tazobactam) IV infused 
over [ADDRESS_77632] (in the PIP -TAZ group) received at least [ADDRESS_77633] subjects completed study drug treatment: 219 (94.0%) subjects in the ZTI -01 group and 222 
(95.7%) subjects in the PIP -TAZ group. 
The primary efficacy endpoint was the proportion of subjects with an overall success (clinical cure and 
microbiologic eradication) in the m -MITT Population at the test -of-cure ( TOC ) Visit. Overall responses 
were programmaticall y determined , and microbiological response presumed that the same bacterial  
species were identical at the Screening and TOC Visits. Overall success was higher in the ZTI -01 group 
(64.7%) compared to the PIP -TAZ group (54.5%). The treatment difference was 1 0.2% (95% CI , -0.4 to  
20.8) and the lower bound of the 95% CI met the prespecified non- inferiority margin of - 15%, 
demonstrating that ZTI -01 was non- inferior to PIP -TAZ.  
The microbiologic eradication analysis (part of Overall Success determination) presum ed that any 
pathogen strain s recovered at baseline and again at TOC  were  identical. Patient isolates from both 
treatment arms underwent blinded pulse -field gel electrophoresis analysis. Th ese molecular data 
confirmed 20 strains with unique identity and a r eanalysis of the primary objective was performed. Using 
this classification, higher overall success rates for both treatment arms was observed; ZTI -01 (69.0%) 
compared to PIP -TAZ (57.3%); the treatment difference was 11.7% (95% CI , 1.3 to  22.1), indicating  that 
ZTI-01 was superior  to PIP -TAZ.  
Both study drugs were well -tolerated, and study drug discontinuations or interruptions due to AEs were 
uncommon. The incidence of TEAEs was higher in the ZTI -01 group (42.1%) compared to the PIP -TAZ 
group (32.0%); howe ver, most TEAEs in the ZTI -01 group were well -described class effects, including 
asymptomatic laboratory abnormalities (e.g., elevated liver transaminases, hypokalemia) or GI disorders. 
The incidence of SAEs was low and similar in the ZTI -01 (5 [2.1%]) and PIP -TAZ (6 [ 2.6%]) groups. No 
unique SAE occurred in >[ADDRESS_77634] in either treatment group. There were no deaths and only one  SAE  
deemed related to ZTI -01 (hypokalemia ) in the study. 
 
 
 
 
DMID Protocol 16- [ADDRESS_77635] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77636] 10, 2017  Table 4: A Es occurring in ≥ 2% of patients r eceiving ZTI -01 in a p hase 2/3 clinical t rial 
Adverse event (%)  Complicated UTIs , including pyelonephritis  
ZTI-01 (N=233)  Pi[INVESTIGATOR_049] -Tazobactam (N=231)  
Nausea  4.[ADDRESS_77637] 7.3 2.6 
Hypokalemia  6.4 1.3 
Headache  2.6 2.2 
2.2. Rationale  
Given the urgent medical need and the spread of bacterial resistance, ZTI -01 may provide a useful option 
for health care providers. ZTI -01 is a proven and useful therapeutic agent with more than 45 years of 
clinical experience documenting that both oral an d IV formulations are effective and well -tolerated in a 
variety of patient populations. In addition to the FDA -approved oral formulation, an IV  formulation of 
fosfomycin (ZTI -01, fosfomycin for injection) would represent a useful therapy option for  difficu lt-to-
treat infections and thus an  important addition to the US therapeutic armamentarium.  
Intrapulmonary penetration of antibiotics is considered a crucial  factor in their ability to treat lower 
respi[INVESTIGATOR_6014] (Rodvold et al, 2011; Ambrose et al , 2010). Pulmonary epi[INVESTIGATOR_71444] 
(ELF) and alveolar macrophages (AMs) have been described  as important sites of infection with common 
extracel lular and intracellular respi[INVESTIGATOR_13531], respectively. Measurement of drug concentrations in 
ELF and AM s by [CONTACT_71486] a practical and reliable method to assess 
intrapulmonary penetration. Knowledge of a drug ’s penetration  (i.e., time course of drug entry and 
magnitude of drug concentration)  in different lung compartments, and the most -likely pathogen ’s location 
within the lung,  can assist in the design of antibiotic dosing regimens to effectively treat lower respi[INVESTIGATOR_71453].  
The development pathway for ZTI -[ADDRESS_77638] of these is to  determine the concentrations of fosfomycin in the ELF and 
AMs  relative  to fosfomycin  concentrations  in plasma . The second is to provide adequate information to 
establish safety of the selected dosing regimen to enable  further evaluat ion of  ZTI-01 in the int ended 
patient population.  
This trial will evaluate a single dose sequence of ZTI -01: three 6 -g doses of fosfomycin , administered as a 
1-hour IV infusion  (+10 minute window) , every [ADDRESS_77639] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77640] strongly associated  with efficacy was the percentage of fosfomycin concentrations above the 
resistance inhibitory concentration (RIC) [% T>RIC] during the dosing i nterval (VanScoy et al , 2015). 
The proposed magnitude % T>RIC associated with net bacterial stasis and a 1 -log 10 and 2- log 10 colony 
forming unit (CFU) reduction in bacterial density over 24 hours was 11.8, 20.9, and 32.7%, respectively. 
Total daily fosfomycin doses of [ADDRESS_77641] fosfomycin 
dosing regimen that did not amplify a drug -resistant bacterial subpopulation was 4 g administered every 8 
hours (VanScoy, et al 2016). An in- vivo study performed in a neutropenic  murine thigh model (Lepak et 
al, 2015) used  dose fractionation to assess PK -PD targets and survival. This study demonstrated ZTI -[ADDRESS_77642] E. coli , K. pneumoniae , and P. aeruginosa, including ESBL -producing  and carbapenem -
resistant phenotypes  in vivo . In this 24- hour model, the index AUC/MIC was most closely linked with 
efficacy. Notably, targets for AUC/MIC and T>Threshold were similar between organism groups. 
Enterobacteriaceae  stasis  was noted at AUC/MIC exposures of ~20 and maximal survival wa s observed at 
exposures similar to stasis endpoints.  
2.3. Potential Risks and Benefits  
2.3.1. Potential Risks  
The oral and  IV formulation s of fosfomycin ha ve been used for > [ADDRESS_77643] participation include procedures associated with the trial (e.g. , blood 
sampling , ECG, and bronchoscopy ) and/or those risks associated with well -characterized , low -incidence 
AEs that have follow ed IV fosfomycin administration.  
IV fosfomycin has a high sodium load, which may result in hypokalemia  and may require  oral or IV 
potassium supplementation in some subjects. Serum electrolyte levels and water balance must be monitored during IV fosfomycin therapy. Caution is advised when IV fosfomycin is used in patients with 
cardiac insufficiency, hypertension, hyperaldosteronism, hypernatremia , or pulmonary edema. 
Acute, potentially life -threatening hypersensitivity reactions ( e.g., anaphylactic shock) may occur rare ly. 
At the first signs of potential anaphylaxis ( i.e., sweating, nausea, cyanosis), the infusion will be 
discontinued. Depending upon the clinical situation, appropriate emergency measures may need to be initiated.  
Antibacterial agent -associated colitis and pseudo -membranous colitis have been reported with nearly all 
antibacterial agents including fosfomycin, and may range in severity from mild to life -threatening. 
Therefore, it is important to consider this diagnosis in patients who present with diarrhea during or after  
IV fosfomycin therapy . 
The following AEs  have been observed commonly or uncommonly  following IV fosfomycin therapy  in 
published literature or clinical trials , or are recognized in labeling  outside the US : 
DMID Protocol 16- [ADDRESS_77644] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77645] 10, 2017  • Common (≥1/100 to <1/10):  nausea, vomiting, diarrhea, abdominal discomfort, i njection -site 
phlebitis , liver enzyme abnormalities,  QT interval prolongation, hypocalcemia, hypokalemia, 
hypophosphatemia, headache  
• Uncommon (≥1/1,000 to <1/100):  decreased appetite, hypernatremia,  dysge usia,  vertigo , 
confusion, visual changes, dyspnea , rash, fatigue , edema,   
• Rare ( ≥1/10,000 to <1/100 0): aplastic anemia, eosinophilia  
• Very rare (<1/10,000): fatty liver (completely reversible after drug discontinuation) , 
anaphylaxis, visual impairment  
• Unknown frequency: pseudomembranous colitis, hepatitis, cholestasis, tachycardia, asthma 
attack, allergic reaction (angioedema, pruritis, urticaria), agranulocytosis , granulocytopenia, 
leukopenia, pancytopenia, thrombocytopenia, neutropenia , confusion 
 
The following potential risks are associated with other study procedures done as part of the  trial:  
• Associated with insertion of peripheral IV catheter  and venous phlebotomy : momentary 
discomfort and bruising ; infection, excess bleeding, clotting, or fainting are unlikely.  
• Associated with  ECG : skin irritation, itching , and redness from placement of  ECG electrode 
pads.  
• Associated with  bronchoscopy : hemoptysis, epi[INVESTIGATOR_3940], local discomfort, fever , sore throat , 
respi[INVESTIGATOR_1506], and respi[INVESTIGATOR_1399] . Sedati ve medications may be given as part of the 
bronchoscopy and may  cause hypotension, lightheadedness , or dizziness; these side effects 
are somewhat common but very transient . Appropriate monitoring equipment and 
medications will be used to promptly identify and manage complications if they 
occur. Bronchoscopy may cause coughing and occasionally gagging. Fever or chills may occur, especially following BAL . Chest pain from atelectasis may occur.  Some people  
experience temporary vomiting, and sore nose /throat. Mild -to-moderate cough may occur  for 
up to [ADDRESS_77646] risk: During the bronchoscopy, subjects will be  placed on supplemental oxygen and 
monitored continuously for oxygen saturation and  electrocardiogram  changes. The topi[INVESTIGATOR_71454] , and limits will be  set and adhered to closely. Pre - and post -
bronchoscopy care will be provided and will include adequate nursing staff and standard post -sedation 
recovery care with direct investigator oversight.  To protect against the risk of QT prolongation, which 
could be caused by [CONTACT_71487], magnesium, calcium, and phosphorus, these electrolytes 
DMID Protocol 16- [ADDRESS_77647] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77648] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77649] 10, 2017  3. OBJECTIVES  AND OUTCOME MEASURE S 
3.1. Study Objectives  
Safety:  
• Determine the safety of multiple doses of ZTI -01 (6 g  dose every 8 hours , administered as a 1 -hour 
IV infusion, for a total of  18 g in  three doses)  
Pharmacokinetic:  
• Determine the plasma and intrapulmonary PK ( ELF and AM  concentrations of ZTI -01) after multiple 
doses of ZTI -01 (6 g  dose every 8 hours , administered as a 1 -hour IV  infusion, for a total of 18 g in 
three doses)  
3.2. Study Outcome Measures  
Safety:  
The safety outcome measure will be the occurrence of adverse events (AEs), summary of physical exam 
findings, vital signs, clinical laboratory tests, and ECGs ( Appendix B ) at any time from the start of study 
drug administration through the end of subject follow -up. 
All subjects who receive at least one  dose of study drug will be included in the safety outcome measure. 
AEs will be collected from the time of dosing on Day 1 through the telephone f ollow -up interview  on Day 
3. TEAEs will be assessed by [CONTACT_11370] y and relationship to the study drug as determined by [CONTACT_1275].  
 
Pharmacokinetics:  
The pharmacokinetic outcome measures will be p lasma and intrapulmonary concentrations of  ZTI-[ADDRESS_77650] dose 
of study drug . The parameters include , but are not limited to :   
• Maximum measured plasma concentration (C max) 
• Area under the concentration v s. time curve (AUC 0-8 and AUC 0-inf) 
• Time to peak concentration (t max) 
• Terminal elimination half -life (t 1/2) 
DMID Protocol 16- [ADDRESS_77651] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77652] 10, 2017  • Terminal -phase elimination rate constant (λ z) 
• Volume of distribution (Vd)  
• Clearance (CL)  
Intrapulmonary PK parameters  will be derived from  the ratios of drug concentrations  in ELF and AMs  to 
simultaneous drug concentrations in plasma for each subject  and summarized for each sampling time. The 
median concentrations of fosfomycin from the BAL sampling times will be used to estimate the AUC 0-[ADDRESS_77653] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77654] of three 6 g doses of ZTI -01 as a 1 h IV infusion ( Table 1). A total of [ADDRESS_77655] dose  (Day - 1) for pre -dosing assessments. The 
Treatment Phase (Day 1 to Day 2 ) will include dosing  6 g of ZTI -01, administered as a 1- hour IV infusion  
(+10 minute window) , every [ADDRESS_77656] IV infusion of ZTI -01 (Table 2).  
Blood samples for PK measurements will be collected before each dose, up to [ADDRESS_77657] IV infusion ( Table 3).  
 Subjects will remain in DEPRU  during the Treatment Phase and will be discharged at least  [ADDRESS_77658] IV infusion  (if safety parameters are acceptable to the i nvestigator). Safety 
assessments will be conducted during the entire Treatment Phase. The Follow -Up Phase will consist of a 
telephone interview on Day [ADDRESS_77659] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77660] s will not be enrolled unless the y meet the following inclusion and exclusion criteria. The 
investigator or other study personnel will  document in the source documents (e.g., the clinical chart) that 
the informed consent form (ICF) was  signed and dated before  study screening. The time and date that  
informed consent was obtained will be recorded in the source documents and electronic  case report form 
(eCRF). The presence of inclusion criteria and the absence of exclusion criteria will be recorded i n the 
eCRF.  
5.1. Subject Inclusion Criteria  
To be considered for study enrollment, subjects must meet all of the following  inclusion criteria:  
1. Healthy1 men and wome n aged  18-45 years with no clinically significant findings2 at Screening 
and Baseline (Day -1 to Day 1)[ADDRESS_77661] has 
another current, ongoing medical condition, the condition cannot meet any of the following 
criteria: 1) first diagnosed within 3 months of enrollment; 2) is worsening in terms of clinical outcome in the last 6 months; or 3) involves need for medication.  
2Including findings on medical history, physical exam, vital signs, 12 -lead ECG, or clinical 
laboratory tests.  
 
2. Body Mass Index (BMI) =  18-30 kg/m2, inclusive, and body weight >50 kg (110 lbs)  
 
3. Females who have been surgically sterilized via bilateral oophorectomy  and/or hysterectomy  at 
least 90 days prior to Screening  are considered lacking childbearing potential and will be eligib le3 
3Postmenopausal females are not eligible, as the definition of menopause would require age 
>45, and all subjects in this study are age ≤45.  
 
4. Females of childbearing potential must have a negative serum pregnancy test at S creening , a 
negative urine pregnancy test at Base line (Day -1 to Day 1 ), and must use acceptable 
contraception4 
4Acceptable contraception methods are restricted to surgical sterilization (bilateral tubal 
ligation ) or successful Essure placement  (permanent, non- surgical, non- hormonal 
DMID Protocol 16- [ADDRESS_77662] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77663] 90 days  after the procedure), 
use of long -acting reversible contraceptive devices (progestin -releasing subdermal implants 
[Nexplanon and Implanon, [COMPANY_006]], copper intrauterine devices [Paragard, Teva], and 
levonorgestrel -releasing intr auterine devices [Mirena, Bayer; Skyla, Bayer; Liletta, 
Allergan/Medicines360]), licensed hormonal products  such as injectables or oral 
contraceptives , barrier methods such as condoms or diaphragm s with spermicidal agents , 
and abstinence from sexual interc ourse with a male partner.  
Subjects must have used the above -listed method for a minimum of [ADDRESS_77664] had vasectomies  
6. Able to abstain from alcoholic beverages within 48 hours before Baseline ( Day - 1 to Day 1)  and 
throughout the Treatment Phase  
7. Able to abstain from caffeine use within 7 days before Baseline ( Day - 1 to Day 1)  and throughout 
the inpatient period  
8. Willing to remain in DEPRU  during the Baseline and Treatment Phases  
9. Have a high proba bility for compliance and completion of the trial   
10. Sign a dated, witnessed, written ICF  
11. Have adequate venous access for infusions and blood draws  
5.2. Subject Exclusion Criteria  
Subjects must meet none  of the following exclusion criteria:  
1. Any surgical or medical condition that in the opi[INVESTIGATOR_71455], distribution, metabolism, or excretion.  
 
2. Any surgical or medical condition that in the opi[INVESTIGATOR_71456] .  
 
DMID Protocol 16- [ADDRESS_77665] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77666] 10, 2017  3. History or presence of cardiovascular disease including coronary artery disease and chronic 
hypertension (systolic pressure >140 mmHg or  diastolic pressure >90 mmHg)  
 
4. Abnormal ECG at screening, as determined by [CONTACT_11150]  
 
5. History or presence of renal impairment or chronic renal disease  
 
6. History or presence of liver disease (ALT , AST , or total bilirubin above the upper limit of 
normal )  
 
7. History or presence of chronic pulmonary dise ase, including asthma , requiring use of medication 
in the year before screening  
8. History of intolerance or hypersensitivity to phosphonic acid derivative antibiotics or any of its 
constituents (i.e., oral or IV fosfomycin)  
9. Have cancer or have a history of cancer within the past [ADDRESS_77667] from undergoing bronchoscopy with BAL  
11. Serum creatinine above the upper limit of normal , or estimated creatinine clearance (CrCl) <60 
mL/min as determined  by [CONTACT_3158] -Gault equation6 
6Cockcroft -Gault equation where age is in years, weight is in kilograms, and serum Cr  is in 
mg/dL  units : 
Males: CrCl (mL/min) = (140 – age) x Weight / (72 x Cr) 
Females: CrCl (mL/min) = [(140 – age) x Weight / (72 x Cr)] x 0.85  
12. History of regular alcohol consumption within 6 months of Baseline (Day - 1 to Day 1 )7  
7History of regular alcohol consumption is defined as an average weekly intake of >14 drinks 
for m ales or >7 drinks for females. One drink is equivalent to 12  g of alcohol: 12 ounces 
(360 mL) of beer, 5 ounces (150 mL) of wine , or 1.5 ounces (45  mL) of 80  proof distilled 
spi[INVESTIGATOR_2120].   
13. History of ≥ 10 pack- years smoking, or history of any nicotine use8 in the 6 months before 
Baseline (Day -1 to Day 1 ) or positive urine cotinine screen at Baseline (Day - 1 to Day 1)9.   
8Including cigarettes, pi[INVESTIGATOR_5836], cigar, chewing tobacco, nicotine patch  
9A positive urine cotinine at screening is allowed if negative at bas eline  
14. History of illicit drug use within 6 months of Baseline (Day -1 to D ay 1)[ADDRESS_77668] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77669] 10, 2017  10Use of cannabinoids with 1 month of Baseline (Day -1 to Day 1) is excluded, but other use 
of cannabinoids within 6 months is permitted.  
15. Use of any prescription drugs , except acceptable contraception methods listed above,  within 30 
days of Baseline (Day -1 to Day 1 ) 
16. Involvement in other investigational studies of any type (drugs, devices, procedures) within 30 
days of Baseline (Day -1 to Day 1 ) 
17. Blood or blood products do nation within 30 days of Baseline (Day -1 to Day 1 ) 
18. Planning e gg or sperm donation any time before  Day 3 follow -up call  
19. Use of any non- prescription medications, vitamins,  consumption >2 times /week of products 
containing genuine  licorice, caffeine, or dietary or herbal supplements within 7 days of Baseline 
(Day -1 to Day 1)[ADDRESS_77670] is intermittent use of acetaminophen at doses ≤2 g/da y. Herbal 
supplements must be discontinued 7 days before  the initial dose of study drug on Day 1.  
20. Presence of any acute illness, including febrile illness with temperature >37.8°C (>100.0°F) , 
within 7 days of Baseline (Day -1 to Day 1 )  
21. Currently pregnant or breastfeeding as determined by [CONTACT_71488]  
22. Positive tests for human immunodeficiency virus (HIV ) 1 and 2 antibodies, hepatitis B surface 
antigen (HBsAg) , or hepatitis C virus  (HCV) antibody  
23. Positive urine drug  or positive breathalyzer test for alcohol at Screening or Baseline (Day - 1 to 
Day 1)  or positive cotinine  at Basel ine (Day - 1 to Day 1)  
24. Weight loss or gain of >10% within 30 days of Baseline (Day - 1 to Day 1 )  
25. Any lab oratory  value at screening or enrollment that is Grade 2 or more  (Appendix B ). A 
laboratory value that is Grade [ADDRESS_77671], or Total 
bilirubin per Exclusion Criteria 6 ; serum creatinine per Exclusion Criteria 11; and serum 
electrolytes including sodium, potassium, calcium, phosphorus and magnesium.  
26. History of infection with SARS -CoV -2 (COVID -19) within 3 months of Baseline (Day - 1 to Day 
1) or unresolved symptoms of COVID -19.  
27. Positive test for SARS -CoV -2 (COVID -19) at Screening or Baseline (Day -1 to Day 1) within [ADDRESS_77672] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77673] 10, 2017   
 
5.3. Treatment Assignment Procedures  
5.3.1. Randomization Procedures  
Subjects will be randomized to a single standardized bronchoscopy with BAL sampling time point  upon 
study enrollment using an assignment schedule as follows: 30 subjects will be randomized 1:1:1:1:1 to 
each of the five  BAL sampling timepoints  ([ADDRESS_77674] IV infusion of ZTI -01). Up to ten  (10) subjects will be enrolled as alternates.  Alternates 
will arrive at DEPRU on Day -[ADDRESS_77675] who fails to present for check- in or who fail s to meet inclusion/exc lusion criteria on 
Day -1 to Day 1. If all scheduled subjects present for check- in and meet Day - 1 to Day 1 
inclusion/exclusion criteria, then alternates will not undergo any further study procedures at that time. In 
that case, alternates may be assigned t o a new bronchoscopy time on a future date, alternate status for a 
future date, or as replacement subjects (see S ection 5.3.4 ). 
Subjects will be enrolled online using the enrollment module of AdvantageEDCSM software. The 
randomization code will be prepared by [CONTACT_71489]. AdvantageEDC
SM will assign each subject to a sampling timepoint after  the demographic and 
eligibility data have been entered.  
Instructions for use of the enrollment module are included in the AdvantageEDCSM User’s Guide. Manual 
back -up procedures and instructions are provided for use in case the site temporarily loses Inter net access 
or the online enrollment system is unavailable.  
5.3.2. Reasons for Withdrawal  and Discontinuation of Study Product Administration 
Subjects may voluntarily withdraw their consent for study participation at any time without penalty or loss of benefits to  which they are otherwise entitled.   
An investigator may also withdraw a subject from receiving the study drug  for any reason. Follow -up 
safety evaluations will be conducted, if the subject agrees. If a subject withdraws or is withdrawn before  
completion of the study, the reason for this decision will be recorded in the  eCRF . The reasons might 
include, but are not limited to the following:  
• Subject no longer meets eligibility criteria  
• Subject becomes noncompliant  
DMID Protocol 16- [ADDRESS_77676] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77677] 10, 2017  • Subjects develops a m edical disease or condi tion, or new clinical finding(s) , for which continued 
participation, in the opi[INVESTIGATOR_871] , might compromise the safety of the subject, interfere 
with the subject's successful completion of this study, or interfere with the evaluation of responses  
• Subject is lost to follow -up 
• Subject becomes pregnant  
The investigator will  be explicit regarding study follow -up (e.g., safety follow -up) that might be carried 
out despi[INVESTIGATOR_71457]. If the subject consents, every attempt 
will be made to follow all AEs through resolution. The procedures that collect safety data for the purposes 
of research will  be included in the original ICF  or the investigator may seek subsequent i nformed consent 
using an IRB /IEC -approved ICF  with the revised procedures.  
The investigator will inform the subject that data already collected will be retained and analyzed even if 
the subject withdraws from the  trial.  
5.3.3. Handling of Withdrawals  and Discontinuation of Admin istration  
Subjects who discontinue will be asked about the reason(s) for their discontinuation and about the 
presence of any AEs. If possible, they will  be seen and assessed by [CONTACT_2413](s). A Es will be 
followed to resolution and/or until deemed stabilized by [CONTACT_941] i nvestigator. Subjects who discontinue  may 
be subject to replacement as described in Section 5.3.[ADDRESS_77678] the 
one blood sampling timepoint that is concurrent with the assigned BAL sampling timepoint, with blood sampling volume that is adequate for testing.  Replacement subjects will undergo study procedures on a 
separate date.  
5.3.5. Terminati on of Study  
The trial  may be terminated at any time at the discretion of the Sponsor , DMID. Other possible reasons 
for study termination include development of significant laboratory toxicities outside of those AEs  
characterized in the label and/or litera ture for the study drug . If the trial is prematurely terminated by [CONTACT_429], any regulatory authority, or the investigator for any reason, the investigator will promptly 
inform the study subjects and assure appropriate therapy or follow -up for the subje cts, as necessary. The 
investigator will provide a detailed written explanation of the termination to the IRB/IEC.  
DMID Protocol 16- [ADDRESS_77679] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77680] 10, 2017  6. STUDY INTERVENTION/I NVESTIGATIONAL 
PRODUCT  
6.1. Study Product Description  
6.1.1. Acquisition  
The non- US commercial drug product that will be used in th e trial is a single vial of ZTI-01 disodium 
powder (4 g presentations with recrystallized succinic acid, in a Type 1 glass vials). Nabriva  Therapeutics 
Inc. will provide DMID an  adequate amount of ZTI -01 to support the  trial, and will ship it  to the 
followi ng address at  Fisher BioServices for storage and site distribution: 
DMID -CMS  
[ADDRESS_77681]  
Germantown, MD [ZIP_CODE]  
Tel: (240) 477- 1350  
Fax: (240) 477- 1360 
E-mail: [EMAIL_1395]  
Sterile water for injection (WFI) will be the diluent a nd will be supplied by [CONTACT_71490].   
Study product will be shipped to DEPRU  upon request and approval by [CONTACT_18127].  
6.1.2. Formulation, Packaging, and Labeling  
ZTI-01 
Each Type 1, glass vial of ZTI -01 contains sterile white powder consisting of 5.28 g of fosfomycin 
disodium (equivalent to 4  g of fosfomycin and 1.28 g of sodium) and the inactive ingredient : 
recrystallized succinic acid. Each gram of ZTI -[ADDRESS_77682] identity – 4 g of  ZTI-01 (fosfomycin for injection), 
lot number, expi[INVESTIGATOR_5695], and the IND caution statement “New Drug  – Limited by [CONTACT_71491] ,” a statement to store at control led room temperature , and a statement that e ach 
vial is for intravenous, single use only.  
WFI 
DMID Protocol 16- [ADDRESS_77683] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77684] 10, 2017  The WFI, [LOCATION_002] Pharmacopeia (USP) is nonpyrogenic and contains no bacteriostatic, 
antimicrobial agent, or added buffer. This product will be used to dilut e the ZTI -[ADDRESS_77685] Storage and Stability  
Glass vials of ZTI -01 will be s tored in a secure and locked research pharmacy, with limited access and 
available to appropriate study personnel only, at controlled room temperature of 20°C to 25°C ( 68°F to 
77°F).  If a temperature excursion outside of 15°C to 30°C (59°F to 86°F)  occurs , the site will discontinue 
use of the vial(s) and notify the DMID Product Support Team (PST) and Nabriva  within 24 hours of 
awareness of the excursion , according to the MOP . 
The Investigator, or a design ee (e.g., research pharmacist) will ensure that all study drugs are 
appropriately stored and in accordance with applicable regulatory requirements.  
Sterile water for injec tion (WFI) will be stored at USP controlled room temperature 20°C to 25°C (68°F 
to 77°F).  
6.2. Dosage, Preparation , and Administration of Study Drug 
Preparation of ZTI -01 for IV infusion will be performed by [CONTACT_71492]’s  Research Pharmacist  according to 
the protocol -specific MOP . The procedure for reconstituting the vials  with s terile water for i njection 
(WFI)  is presented in  Table 5 . 
 
Table 5: ZTI -01 dose preparation guidelines  
ZTI-01 
(fosfomycin) 
dosage  Number of vials 
reconstituted with 
20 mL of sterile WFI 
added to each vial  Volume of 
Sterile WFI to 
dissolve ZTI -01 
powder Volume of 
dissolved ZTI -
01 to be added 
for infusion  Volume of 
WFI to be 
added for 
infusion Total 
volume for 
infus ion 
6 g 2 40 mL (20 mL 
for each of two 
vials)  30 mL  
(15 mL from 
each of two 
vials)  170 mL  200 mL  
Each 1  g dose of ZTI -01 contains 330 mg of sodium. Due to the salt load of the formulation, s terile WFI 
will be used to reconstitute each ZTI -01 vial and to prepare the 200 ml ZTI -01 infusion (Table 6 ).   
A total of two [ADDRESS_77686] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77687] 10, 2017  will be used to prepare the infusion solution as follows, and as further detailed in the MOP : Using aseptic 
technique, withdraw an equal amount (15 mL) from each reconstituted vial (a total volume of 30 mL from 
both vials). The solution that is left in each vial will  remain “unused. ” Add the 30 mL of diluted ZTI -01 
to 170 mL of s terile WFI  to yield  the 200  mL total volume for infusion. The storage for the infusion bag, 
before  administration, is limited to 4 hours at room temperature  (20- 25°C)  or 24 hours  at refrigerated 
conditions  (2 - 8°C) .  
  
Table 6: ZTI -01 (disodium fosfomycin) reconstitution with WFI  
Dose  Preparation Steps  
6 g Step 1:  Add 20 mL of sterile WFI to each of two vials of ZTI -01 powder  
 
Step 2:  Draw 30 mL total from both vials of  diluted ZTI -01. Note: Draw an equal 
amount (15 mL) from each dissolved vial; the 5 m L left in the vials remain “unused .” 
 Step 3:  Add the 30 mL of dissolved ZTI -01 to 170 mL of sterile WFI to yield the 200  
mL total volume for infusion. 
Note: The p harmacy will need to use/reconstitute 2 vials for each 6  g dose.   
ZTI-01 should always be administered as a 200 mL infusion over 1 hour  (+10 minute window) .  
Note: Each 1  g dose of ZTI -01 contains 330 mg of sodium; a [ADDRESS_77688] receiving 3 doses per protocol will  be administered 5940 mg of sodium. 
The ZTI -01 6 g infusion solution will  be infused intravenously  over 1 hour  (+10 minute window)  using an 
IV infusion pump at a rate set to 200 mL/hr. A dose  will be administered every 8 hours for 3 doses.  
Administering s terile WFI  alone ( i.e., with no additives) may increase risk of hemolysis in some subjects 
due to hypotonicity. Although the IV infusion of sterile W FI alone is contraindicated, the addition of ZTI -
01 to s terile W FI is appropriate and recommended for IV  adm inistration. The use of 0.9% NaCl (isotonic 
saline ) for infusion with ZTI -[ADDRESS_77689] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77690] 10, 2017  6.4. Accountability Procedures for the Study Drug 
Chain of custody will be documented between the on- site pharmacy and the clinical staff responsible for 
administering the study drug.  
The Site Principal Investigator (PI) is responsible for the distribution and disposition of the study drug , 
and has ultimate responsibility for accountability. The P I may delegate to the Site Research Pharmacist 
responsibility for study drug accountability. The Research Pharmacist will be responsible for and will  
maintain and docum ent logs of receipt, accountability, dispensation, storage conditions, and final 
disposition of study drug. Upon completion or termination of the trial , all unused and used vials of ZTI -01 
will be disposed according to DEPRU’s  standard operating procedures  (SOPs) after accountability. T he 
investigator  is responsible for  ensur ing that no study drug is  disposed until it  is fully accounted for by [CONTACT_36102].  
6.5. Assessment of Subject Compliance with Study Drug   
Study staff will be present for and during all study drug administration s. Visual inspection by [CONTACT_71493] . It is important to 
document that the entire 200 mL infusion is administered with each dose. All interruptions or premature 
termination s of infusion will  be documented.  
6.6. Concomitant Medications/Treatments  
Medications to treat any AEs the subject experiences during the trial  are permitted. All information on 
concomitant medications will be recorded on the subject’s eCRF and will  include the name [CONTACT_71515] (start/stop times), dosages , and route. The intermittent 
intake of acetaminophen (maximum 2 g/day) is permitted throughout t he trial if approved by [CONTACT_941] S ite PI. 
Subjects are required to refrain from the use of all prescription medications for at least [ADDRESS_77691] PK sample is taken. T he consumption 
of bev erages containing alcohol is prohibited for 48 hours before  Baseline ( Day - 1 to Day 1)  until 
completion of the Treatment Phase. The consumption of caffeine is prohibited for 7 days prior to Baseline 
(Day -1 to Day 1)  and during the Treatment P hase. Herbal supplements and over -the-counter  meds 
(except acetaminophen at doses ≤2 g/day) must be discontinued [ADDRESS_77692] dose of study drug 
until completion of the Treatment Phase. The use of illegal drugs is prohibite d within the  6 months  prior 
to Baseline (Day -1 to Day 1)  and is not permitted while subjects are enrolled in this study. A urine drug 
screen will be performed at S creening. If a subject is unable to comply with the restrictions described 
above, the subjec t’s continued participation in the trial will be re -evaluated by [CONTACT_093].  
DMID Protocol 16- [ADDRESS_77693] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77694] 10, 2017  7. STUDY SCHEDULE  
7.1. Screening  (Day -30 to Day -1)   
Subjects will  be screened within 30 days before  Enrollment/ Baseline (Day - 1 to Day 1). A sufficient 
number of individuals  will be screened to identify [ADDRESS_77695] has signed the IRB -
approved ICF , the following evaluations will be performed and/or recorded in the  eCRF : 
• Demographics (date of birth, gender, and race/ethnicity)  
• Complete medical history and prior medication history to include all drugs taken (including non-
prescription and herbal products) within 30 days before  screening procedures  
• Physical exam  to include  the following organs and organ systems : vital signs (temp erature, blood 
pressure, respi[INVESTIGATOR_697], heart rate, peripheral oxygen saturation) , skin, head and neck, lungs, heart, 
liver, spleen, extremities, lymph nodes, and nervous system.  
• Record history of alcohol (within prior 6 months) and tobacco use (lifetime)  
• Height and weight to determine BMI  
• Standard 12- lead ECG  
• Laboratory tests  (urine and blood specimens) as outlined in Appendix A  
• Urine drug s creen, urine cotinine , and a lcohol test (breathalyzer)  
• Serum pregnancy test for females of childbearing potential  
• Collect birth control method and counsel subjects on acceptable contraceptive measures  
• Counsel participants to avoid consumption of non- prescription medications, vitamins, licorice (in 
large amount s), caffeine or dietary or herbal supplements in the 7 days prior to confinement  and to 
avoid consumption of beverages and foods containing alcohol for 48 hours prior to confinement  
• Confirm all inclusion and exclusion criteria are fulfilled 
• SARS -CoV -2 (COV ID-19) test will occur within 72 hours prior to admission at the Screening Visit 
(Day -30 to Day -1) if Screening Visit occurs between (Day -3 to Day -2)  
7.2. Enrollment/Baseline  (Day -1 to Day 1)  
Subjects will be admitted to DEPRU on Day -[ADDRESS_77696] dose of study drug on Day 1. 
After admission to DEPRU, the following Enrollment/Baseline tests and evaluations will be performed . 
DMID Protocol 16- [ADDRESS_77697] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77698] 10, 2017  All Enrollment/Baseline tests and evaluations  will be p erformed within 36 hours of randomization to a 
bronchoscopy time . 
• Physical exam  to include the following organs and organ systems:  vital signs ( temperature, blood 
pressure, respi[INVESTIGATOR_697], heart rate, peripheral oxygen saturation ), skin, head and neck, l ungs, heart, 
liver, spleen, extremities, lymph nodes, and nervous system  
• Weight  
• Review changes in the subject’s medical history since screening  
• Laboratory tests  as outlined in Appendix A  
• Urine pregnancy test for females of ch ildbearing potential  
• Counsel subjects on acceptable contraceptive measures 
• Urine drug s creen, urine cotinine , and alcohol breath test (breathalyzer)  
• Review prior concomitant medication history since screening  
• Record non- pharmacologic treatments/procedures within 72 hours before enro llment in the  eCRF  
• Confirm all inclusion and exclusion criteria are fulfilled 
• Standard 12- lead ECG  
• Randomize  to a bronchoscopy time  
• Place two peripheral IVs  
•  SARS -CoV -2 (COVID -19) test will occur within 72 hours prior to admission at the Baseline Visit 
(Day -1 to Day 1) if test was not administered during Screening Visit   
7.3. Day 1 to Day 2  
• Administ er study drug  to subjects every 8 hours for a total of 3 doses.  
• Obtain v ital signs, including heart rate, blood pressure, temperature, respi[INVESTIGATOR_71458] , and at approximately 0.5, 1, 2, and 5 hours after the 
start of each dose of study drug  (T0 = time of each infus ion start)  
• Review and record any AEs and SAEs  
• Review and record any concomitant medications , vitamins and herbal supplements  
• Perform a s tandard 12- lead ECG  within [ADDRESS_77699] ( last) dose of study drug  
DMID Protocol 16- [ADDRESS_77700] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77701] 10, 2017  • Obtain PK blood samples at 15 timepoints: before  (within 10 minutes) the first, second, and third 
doses of study drug, at 30 minutes (during infusion), 1 hour (within 5 minutes after the end of 
infusion), [ADDRESS_77702] infusion of ZTI -01, and at  
30 minutes  (during infusion ), 1 hour  (within 5 minutes after the end of infusion) , [ADDRESS_77703] ( last) infusion of ZTI -01 
• Measurement of sodium, potassium, magnesium, calcium, and phosphorus approximately 2 hours 
prior to the assigned bronchoscopy timepoint  
• A standardized bronchoscopy with BAL sampling will be performed  at single timepoint based on 
each subject’s schedule assignment at either [ADDRESS_77704] ( last) infusion of ZTI -01 
• Collect a b lood sample to measure serum urea concentration just before or during bronchoscopy  
7.4. Day 2 (Day of Discharge from DEPRU)  
• Laboratory tests  and ur inalysis as outlined in Appendix A   
• Review and record any AEs and SAEs  
• Review and record any concomitant medications , non- pharmacologic treatments or procedures  
• Perform a  physical exam  to include the following organs and organ systems: vital signs (temperature, 
blood pressure, respi[INVESTIGATOR_697], heart rate, peripheral oxygen saturation), skin, head and neck, lungs, 
heart, liver, spleen, extremities, lymph nodes, and nervous system; measur e weight before  discharge  
7.5. Day 3 (Telephone Follow-up Call)  
A telephone call follow -up will be conducted the day following each subject’s discharge from DEPRU  to 
ask about subject’s clinical  status, concomitant medications, and AEs/SAEs . In the event of ong oing or 
new AEs /SAEs , subjects may be asked to return to DEPRU for evaluation at the investigator’s discretion. 
Ongoing AEs /SAEs  will be followed until resolved or stable/improving over two assessments and no 
further intervention is required.  
7.6. Early Termination Visit  
If the subject is prematurely discontinued from the trial , the same exit procedures as those performed on 
Day [ADDRESS_77705] has an ongoing clinically significant 
abnormality at this visit and/or the clinical laboratory evaluations reveal a clinically significant laboratory 
abnormality, as deemed appropriate by [CONTACT_941] i nvestigator or designee. Clinically significant laboratory 
DMID Protocol 16- [ADDRESS_77706] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77707] 10, 2017  abnormalities  will be monitored periodically until resolution or until they are considered irreversible, or 
until there is a satisf actory explanation for the changes observed. 
7.7. Unscheduled Visit (if needed)  
• Review and record any AEs and/or SAEs  
• Review and record any concomitant medications , non- pharmacologic treatments or procedures  
• Perform a  physical exam  to include the following organs and organ systems: vital signs (temperature, 
blood pressure, respi[INVESTIGATOR_697], heart rate, peripheral oxygen saturation), skin, head and neck, lungs, 
heart, liver, spleen, extremities, lymph nodes, and nervous system  
• Obtain  a standard 12- lead ECG at  the investigator’s discretion  
• Other studies as clinically indicated at the investigator’s  discretion  
DMID Protocol 16- [ADDRESS_77708] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77709] 10, 2017  8. STUDY PROCEDURES/EVALUATIONS  
8.1. Clinical Evaluations  
Medical history: history or presence of prior and current medical conditions or significant surgical 
procedures  
Physical exam: overall physical assessment  (to include vital signs [temperature, blood pressure, 
respi[INVESTIGATOR_697], heart rate, peripheral oxygen saturation], skin, head and neck, lungs, heart, liver, spleen, extremities,  lymph nodes, and nervous system) and weight  will be collected at Screening, Baseline ( Day -
1 to Day 1) and Day 2 (day of discharge). Height will be measured and BMI calculated at screening only.  
ECG: performed in the supi[INVESTIGATOR_1662] -recumb ent position aft er rest ing for at least 10 minutes at 3 
timepoints: Screening, Baseline (Day -1 to Day 1 ), and Day [ADDRESS_77710] ( last) dose of 
study drug . Each ECG will be  interpreted  and abnormal results acted upon by [CONTACT_71494] (Screening and Baseline ECG abnormalities per Exclusion Criteria, Day 2 ECG 
abnormalities per  Appendix B
). In case of premature discontinuation, ECG will  be performed before  
discharge.  
Vital sig ns: heart rate, blood pressure, temperature, respi[INVESTIGATOR_697], and peripheral oxygen saturation will 
be measured with the subject in the supi[INVESTIGATOR_1662] -recumbent position, will be obtained at the following 
timepoints: Screening, Baseline ( Day -1 to Day 1) , before  each of [ADDRESS_77711]’s bronchoscopy, that timepoint will be measured immediately 
before  the start of bronchoscopy. If vital sign s are abnormal, repeat readings will be obtained up to twice 
more (total of [ADDRESS_77712] one), 5- 10 minutes apart. If the y remain abnormal, 
unscheduled vital signs will be repeatedly obtained until they normaliz e (at investigator’s discretion ).  
Prior/Concomitant Medications/Treatments: information regarding allergies and use of  prescrip tion 
medications, non- prescription medications , herbal supplements, nicotine , caffeine, alcohol, and illicit 
drugs will be obtained at Screening, Baseline ( Day - 1 to Day 1) , Treatment ( Days 1 -2), Day  [ADDRESS_77713]’s enroll ment as required.  
8.2. Laboratory Evaluations  
8.2.1. Clinical Laboratory Evaluations  
Serum c hemistry: albumin, glucose, blood urea nitrogen (BUN), potassium, magnesium, calcium, 
sodium, total protein, creatinine, triglycerides, total cholesterol, creatine phosphokinase (CPK), 
phosphorus, alkaline phosphatase (A LP), AST, ALT, total bilirubin, direct bilirubin, and lactate 
dehydrogenase (LDH) will be collected at Screening and Day [ADDRESS_77714] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77715], 
ALT, and total bilirubin will be collected at Baseline (Day -1 to Day 1). Sodium, potassium, magnesium, 
calcium, and phosphorus will be collected approximately 2 hours  prior to the assigned bronchosc opy 
timepoint.  
Hematology: CBC with differential (hemoglobin, hematocrit, platelet count, white blood cell (WBC) 
count, neutrophils, lymphocytes, monocytes, eosinophils, basophils) will be collected at Screening and 
Day 2 before  of discharge.  
Coagulation:  PT and aPTT will be collected at Screening and Day  2 before discharge.  
Urinalysis: l eukocyte esterase, blood, pH, specific gravity, glucose, protein. A microscopic test will  be 
performed if urinalysis is abnormal. The m icroscopic urinalysis result for the presence of blood will 
supersede the dipstick urinalysis  result . Urinalys es will be performed  at Screening and Day  [ADDRESS_77716]: a serum pregnancy test will be performed  on all females of childbearing 
potential at Screening , a urine pregnancy test will be performed on all females of childbearing potential at 
Baseline (Day -1 to Day 1 ). 
Test for SARS -CoV -2 (COVID- 19) at Screening  or Baseline (Day -1 to Day 1) within 72 hours of 
admission  
Screening for Chronic Infections : HIV antibody, HBsAg, and HCV  antibody will be measured  at 
screening  
Alcohol ( breathalyzer) test, urine c otinine, and urine d rug testing: performed at Screening and Baseline 
(Day -1 to Day 1 ). Urine will be collected and tested separately for cotinine and illicit  drugs: barbiturates, 
benzodiazepi[INVESTIGATOR_1651], THC, cocaine, opi[INVESTIGATOR_858], and amphetamine /methamphetamine . 
Urea: a b lood sample for plasma urea concentration will be obtained just before  or during each subject’s 
scheduled bronchoscopy. 
8.2.2. Bronchoscopy and Bronchoalveolar Lavage (BAL)  
Each subject will be assigned to one bronchoscopy sampling timepoint. The bronchoscopy sampling 
times will be at [ADDRESS_77717]  (last) 
infusion of ZTI -01. A total of [ADDRESS_77718]’s bronchoscopy timepoint. Subjects with grade 2  or higher abnormalities  (Appendix B ) in 
these electrolyte s will not receive any further study product and will not undergo bronchoscopy. 
Bronchoscopy will be performed in a standardized fashion according to the MOP. Topi[INVESTIGATOR_71459]. If needed, 1.0% per cent lidocaine 
DMID Protocol 16- [ADDRESS_77719] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77720]. A fiberoptic bronchoscope will be inserted into the right middle lobe. 
Four 50- mL aliquots of sterile normal saline will be instilled into the right middle lobe and each specimen 
will be immediately aspi[INVESTIGATOR_337] d and placed on ice. BAL samples for PK measures will be obtained ± [ADDRESS_77721]’s assigned sampling time. The start and stop times of BAL  will be recorded on 
the eCRF . 
Subjects will be continuously monitored during bronchoscopy. Blood pressu re, heart rate, respi[INVESTIGATOR_697], 
and peripheral oxygen saturation will be recorded before and at the end of bronchoscopy. Subjects will undergo cardiac monitoring during bronchoscopy.  
8.2.3. Pharmacokinetic Blood and BAL Samples  
An assay to measure ZTI -01 concentrations in plasma, BAL, and cell pellet samples and urea in plasma 
and BAL samples will be conducted at a central analytical lab using a validated LC -MS/MS bioanalytical 
assay. Timing of samples will be with respect to the start of each dose of stud y drug (pre -dose and post -
infusion start, when applicable). The date and time of each PK sample and BAL collection will be recorded in the e CRF. Blood PK samples will  be drawn for all subjects within the following windows: -
10 to - 1 minute for scheduled sa mples at pre- dose; ±5 minutes for scheduled samples at 30 minutes , 1 
hour 15 minutes, and 2 hours; +0-5 minutes from end of infusion for the scheduled sample at 1 hour; and 
±15 minutes for scheduled samples at 5, 8, and 12 hours. BAL samples for PK (fosfom ycin and urea 
assays)  will be obtained within +/ - [ADDRESS_77722] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77723] 10, 2017   
 
Table 7: Pharmacokinetics sampling times  
Study day  Dosing  Blood s ampling t imes*  BAL s ampling t imes§ 
Day [ADDRESS_77724] dose:  
ZTI-01 6 g IV infusion 
over 1  hour  (+10 minute 
window)  All subjects:  
Pre-dose ( -10 to - 1 minutes ), 
30 minutes (during the 1- hour 
infusion), and [ADDRESS_77725] dose  No sampling  
Second dose:  
ZTI-01 6 g IV infusion 
over 1  hour  (+10 minute 
window)  All subjects:  
Pre-dose ( -10 to - 1 minutes ) No sampling  
Third dose:  
ZTI-01 6 g IV infusion 
over 1  hour  (+10 minute 
window)  All s ubjects:  
Pre-dose (-10 to - 1 minutes ), 
30 minutes  (during the 1- hour 
infusion), and [ADDRESS_77726]  (last) infusion of ZTI -[ADDRESS_77727]:  
Complete a single bronchoscopy with BAL at one of the five sampling times: 30 minutes (during 
the 1- hour infusion), [ADDRESS_77728]  
(last) infusion of ZTI -01 
Day 2  
At Discharge  No further dosing  All s ubjects:  
[ADDRESS_77729] ( last) infusion of ZTI -01 No sampling  
* Blood PK samples will be drawn for all subjects within the following windows: - 10 to - 1 minutes for scheduled 
samples at pre -dose; ±5 minutes for scheduled samples between 30 minutes , 1 hour 15 minutes,  and 2 hours;  +0-5 
minutes from end of infusion for the scheduled sample at 1 hour;  ±[ADDRESS_77730] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77731] 10, 2017  § BAL samples  for PK (fosfomycin an d urea)  will be drawn ±[ADDRESS_77732] before or 
during the bronchoscopy . 
8.2.4. Specimen Preparation, Handling, and Shippi[INVESTIGATOR_71460] -specific MOP for detailed instruction for collection, processing, labeling, 
storing, handling and shippi[INVESTIGATOR_007]. 
[IP_ADDRESS]. Instructions for Specimen Preparation, Handling, and Storage  
All samples collected and processed for PK analysis will be shipped in accordance with the MOP  to 
DMID -CMS at the address below,  and will be tracked using DMID ’s Global Trace Sample Tracking 
system . 
 
DMID -Clinical Materials Services  (Fisher BioServices ) 
[ADDRESS_77733]  
Germant own, MD [ZIP_CODE]  
Tel: 240- 477-1350, 
Fax: 240- 477-1360 
Email: dmid.cms @thermofisher.com  
Blood samples: For each blood sample timepoint (according to Sections 8.2.1  and 8.2.3), approximately  4 
mL of blood will be drawn into a vacutainer tube and will be processed according to the MOP.  
BAL samples: BAL samples will be collected according to Section 8.2.2 and processed for PK and urea 
measurements according to the MOP.  
Specim en shipment: Plasma and BAL cell pellet samples will be shipped overnight on dry ice to DMID -
CMS, which will then send  one set of samples to the bioanalytical lab performing the PK analysis. See 
the MOP for details for shippi[INVESTIGATOR_007]. 
 
DMID Protocol 16- [ADDRESS_77734] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77735] of the trial and for reporting 
AEs and SAEs according to the  protocol and a pplicable federal regulations. An Independent Safety 
Monitor (ISM) is a physician experienced i n the conduct of clinical studies , located close to DEPRU , and 
appointed to independently review all SAEs  and related Grade [ADDRESS_77736] a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including a clinically significant 
laboratory abnormality ), symptom, or disease temporally associated with use of the  study drug , whether 
or not it is deemed related to the study drug . The occurrence of an AE may come to the attention of study 
personnel during study visits and interviews of a study subject  presenting for medical care, or upon 
review by a study monitor. T he period of observation for AE reporting will begin on Day [ADDRESS_77737] dosing and continue through the final visit, a follow -up call  on Day 3.  
All AEs including local and systemic reactions not meeting the criteria for SAEs  will be captured on the 
appropriate  eCRF . Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to study drug  (assessed only by [CONTACT_71495] a diagnosis), outcome, action taken , and time of resolution/stabilization of the AE . All AEs 
occurring while on study will  be documented appropriately regardless of relationship. All AEs will be 
followed until they  adequately  resol ve or are  determined by [CONTACT_978] [INVESTIGATOR_71461] (stabl e or 
improving over two assessments and no further intervention required). Any medical condition that is present at the time that the subject is screened will be considered as a baseline finding and not reported as 
an AE. However, if its G rade increases at  any time during the trial such that it meets the AE definition 
specified above, it will be recorded as an AE.  
All systemic and laboratory AEs will  be graded using the Adverse Event Toxicity Grading Scale 
(Appendix B
). Laborat ory toxicity grading will be determined by [CONTACT_71496] 16- [ADDRESS_77738] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77739] was enrolled in the trial with a la boratory value that is outside the 
reference range, but within the acceptable ranges , , an AE will be recorded if it otherwise meets the 
definition of AE in Section 9.3 and the on- study value is higher (if initially high) or lower (if initially 
low) than the screening value.  
Severity of Event:   
All AEs will be assessed by [CONTACT_71497] -defined grading system in  Appendix B . 
Changes in the severity of an AE will  be documented to allow an assessment of the duration of the AE  at 
each level of intensity to be performed. A Es characterized as intermittent require documentation of onset 
and duration of each epi[INVESTIGATOR_1865]. 
Relationship to Study Products:  
The clinician’s assessment of an AE's relationship to the study drug  is part of the documentation process, 
but it is not a factor in determining what is or is not reported in the trial . If there is any doubt as to 
whether a clinical observation is an AE, it  will be reported. All AEs will  have their relationship to the 
study drug  assessed using the terms “ related ” or “not related. ” In a clinical trial, the study drug  must 
always be suspect. To help assess relatedness, the following guidelines are used.  
• Related : There is a reasonable possibility that the study drug  caused the AE . Reasonable possibility 
means that there is evidence to sug gest that  the study drug caused  the AE . 
• Not Related : There is not a reasonable possibility that the study drug  caused the AE.   
9.2.2. Serious Adverse Events  
An AE  or suspected AE  is considered “serious” if, in the view of either the investigator or S ponsor, it 
results in any of the following outcomes:  
• Death,  
• a life -threatening AE ,  
• An adverse event is considered life- threatening if, in the view of either the site principal investigator 
[INVESTIGATOR_10157], its occurrence places the patient or subject at immed iate risk of death. It does not include 
an adverse event that, had it occurred in a more severe form, might have caused death.  
• inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant incapacity or substantial dis ruption of the ability to conduct normal life 
functions, or  
• a congenital anomaly/birth defect.   
DMID Protocol 16- [ADDRESS_77740] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77741] 10, 2017  • Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_6721], based upon appropriate medical judgment they may jeopardize the 
subject and may require medical or surgical intervention to prevent one of the outcomes listed in this 
definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an e mergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
All SAEs will be: 
• Assessed for severity and relationship to the study drug and alternate etiolog y, 
• Recorded on the appropriate SAE data collection form and eCRF , 
• Followed through resolution, 
• Reviewed and evaluated by [CONTACT_71498] (as deemed necessary), SMC  (periodic review unless related), 
DMID, and IRB.  
9.2.3. Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  
A licensed study physician will make the determination of seriousness, severity, and causality, provide a 
medical evaluation of adverse events, and classify adverse events based upon medical judgment. Abnormal laboratory test values or abnormal clinical findings for all enrolled subjects, including values 
and findings noted at screening and baseline, will be assessed using the toxicity scales in Appendix B . 
Abnormal values and findings noted at S creening or B aseline will only be considered AEs if they increase 
in grade  after study product administration. For abnormalities noted from the time of study drug 
administration, any Grade 1 or higher laboratory abnormality listed on the toxicity table in Appendix B
 
will be entered in the database as an AE. Abnormal clinical/laboratory findings will be collected, assessed, documented, reported, and followed appropriately.  
9.3. Reporting Proc edures  
AEs will be reported from the time of dosing on Day [ADDRESS_77742] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77743] 10, 2017  The Site PI  [INVESTIGATOR_71462]. DMID will be 
responsible of informing the US Regulatory Authority of the SAE as per federal requirements.  
9.3.1. Serious Adverse Events  
Any AE that meets a protocol -defined serious criterion will be submitted immediately (within 24 hours of 
site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_77744] ive, Suite 650  
Bethesda, MD [ZIP_CODE], [LOCATION_003]  
SAE Hot Line: 1 -[PHONE_889] (US) or 1- [PHONE_1728] (outside US)  
SAE FAX Number: 1 -[PHONE_1729] (US) or 1- [PHONE_891] (outside US)  
SAE Email Address: [EMAIL_1393]  
In addition to the SAE form, select SAE data fields wil l also be entered into the DCC system ( e.g., 
Advantage EDC ). Please see the protocol -specific MOP for details regarding this procedure.  
Other supporting documentation of the SAE  may be requested by [CONTACT_71499].  
DEPRU  will send a copy of the SAE report(s) to the ISM when they are provided to the DMID 
Pharmacovigilance Group. The DMID Medical Monitor and DMID Clinical Project Manager will be 
notified of the SAE by [CONTACT_71500]. The DMID Medical Monitor will review 
and assess the SAE for regulatory reporting and potential impact on subject safety and protocol conduct.  
At any time after completion of the study, if the Site PI  [INVESTIGATOR_29353]- investigator becomes aware of 
an SA E that is suspected to be related to the study drug , the Site PI  [INVESTIGATOR_29353]- investigator will 
report the SAE  to the DMID Pharmacovigilance Group.  
9.3.2. Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the in vestigator, the IND s ponsor  DMID will report any suspected AE that i s 
both serious and unexpected. DMID will report an AE  as a suspected adverse reaction only if there is 
evidence to suggest a causal relationship between t he study drug and the AE . DMID will notify FDA and 
all participating investigators (i.e., all investigators to whom the Sponsor is providing drug under its  INDs 
or under any investigator’s IND) in an IND safety report of potential serious risks from clinical trials or any other source, as soon as possible, but in no case later than [ADDRESS_77745] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77746] 10, 2017  also notify FDA of any unexpected fatal or life -threatening suspected AE  as soon as possible but in no 
case later than 7 calendar days after the Sponsor’s initial receipt of the information. Relev ant follow -up 
information to an IND safety report will be submitted as soon as the information is available. Upon 
request from FDA, DMID will submit to FDA any additional data or information that the agency deems necessary, as soon as possible, but in no c ase later than [ADDRESS_77747].  
All SAEs  designated as “not related” to the study drug  will be reported to the FDA at least annually in a 
summary format.  
9.3.3. Reporting of Pregnancy 
Pregnancies occurring in study subjects will be reported via AdvantageEDCSM on the Pregnancy Report 
form. All pregnancies occurring during the trial will  be followed for information regarding the course of 
pregnancy and any outcome, delivery and condition of the newborn. Follow -up will be provided by [CONTACT_71501] M edical Monitor (or designee) in a timely manner.  
9.4. Type and Duration of Follow -up of Subjects after Adverse Events  
All AEs  will be followed until  resolution or until determined by [CONTACT_978] [INVESTIGATOR_71461] 
(stable/improving and no further intervention required) . 
9.5. Halting Rules  
If any of the halting rules, as outlined below, is met, further enrollment  and dosing  will be withheld until 
the SMC reviews the sa fety data and provides its recommendations .  
• Two subjects experience any related Grade 3 systemic AE   
• Two subjects experience the same related Grade 3 laboratory AE (per Medical Dictionary for Regulatory Activities High Level Group Term ) 
• One subject experiences a related SAE  
A decision to reinitiate the trial and proceed with study drug administration  will be made by [CONTACT_71502].  
If the foll owing individual halting rule is met, the individual will not undergo further dosing or study 
procedures.  
• Subject experiences a  grade [ADDRESS_77748] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77749] 10, 2017  9.6.1. Independent Safety Monitor (ISM)  
An ISM will oversee the safety of subjects and provide independent evaluation of all SAEs and related 
Grade [ADDRESS_77750] -related issues and 
resolve queries generated by [CONTACT_71498], DMID Medical Monit or, and SMC, as applicable.  
9.6.2. Safety Monitoring Committee (SMC)  
An SMC will be appointed to monitor subject safety.  The SMC will consist of independent evaluators 
who will have no relationship with the conduct of the trial. The SMC will operate under the rules of a DMID -approved charter that will be written at the organizational meeting of the SMC. In the charter, 
meeting frequency and each data element that the SMC will assess will be clearly defined.  
The SMC will review safety data for increased rate of occurrence of serious suspected AEs . If halting 
rules are met, more frequent meetings may be held. Ad hoc meetings may also be held to address any 
safety issues that may arise.  
If the trial is halted , the SMC will be consulted to review the data and provide a recommendation related 
to the continued dosing of the subjects.  
The SMC will advise DMID of its recommendations. At the end of study enrollment, the SMC will 
review  clinical safety and PK  data , and provide recommendations  regarding further safety assessm ents in 
studies with ZTI -01. Since the study is an open- label trial, a statistician may provide independent analyses 
to the SMC as needed.  
DMID Protocol 16- [ADDRESS_77751] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77752] of the trial  comp lies with 
21 CFR 11, 21 CFR 50, 21 CFR 54, 21 CFR 56, 45 CFR 46, 21 CFR 312 GCP and ICH Guidelines, and 
DMID guidelines, as appropriate.  
10.1. Site Monitoring Plan  
Site monitoring is conducted to ensure that the human subjects ’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality and meet 
Sponsor, ICH/GCP guidelines , and applicable regulations, and that th e trial is conducted in accordance 
with the pro tocol, protocol -specific MOP , and applicable Sponsor SOPs . DMID, the S ponsor, or its 
designee will conduct site -monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals as defined by [CONTACT_71503]. Monitoring visits will include, but are not limited to, review of regulatory files, 
accountability records,  eCRF s, ICFs , medical and laboratory reports, and protocol and GCP compliance. 
Site monitors will have access t o DEPRU , study personnel, and all study documentation according to the 
DMID -approved site monitoring plan. Study monitors will meet with the S ite PI  [INVESTIGATOR_71463], and will document site visit findings and discussions.  
DMID Protocol 16- [ADDRESS_77753] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77754] as a bridge between the new 
IV formulation and the approved oral reference drug.  
These data could permit the application of previously submitted information (e.g. safety , pharmacology , 
toxicology, genotoxicity, carcinogenicity) in support of the new IV  formulation.   
This study will also provide adequate information to confirm the safety and PK of ZTI -[ADDRESS_77755] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77756] 10, 2017  Table 8: Probability of observing at least one event for a range of true event rates based on 
a sample size of n=30 subjects  
True Event 
Rate Probability of 
observing 1 or 
more events  
0.1%  3% 
0.5%  14% 
1% 26% 
2% 45% 
5% 79% 
7% 89% 
10% 96% 
15% 99% 
11.3. Final Analysis Plan  
Analysis Populations:  
All subjects who receive any amount of ZTI -[ADDRESS_77757] the one blood 
sampling timepoint that is concurrent with the BAL sampling timepoint, with blood sampling volume that 
is adequate for testing.  
Safety :   
The safety outcome measure will be the occurrence of AEs (Appendix B ) at any time from the start of 
study drug administration through the end of  subject follow -up. 
All subjects in the safety population will be  included in the s afety analyses. AEs will be collected from 
the time of do sing on Day 1 through the Telephone Follow -Up Interview  on Day 3. TEAEs will be 
tabulated by [CONTACT_926]  (mild, moderate, or severe), type (MedDRA system organ class and preferred term), 
and by [CONTACT_71504].  TEAEs will be summarized both 
by [CONTACT_71505]. For summaries by [CONTACT_12035] , subjects will be tabulated according to the most 
severe grade of AE experi enced ( each subject counted only once per type of AE).  For summaries of 
DMID Protocol 16- [ADDRESS_77758] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77759] 10, 2017  frequency, each AE (by [CONTACT_24975]) will be tabulated by [CONTACT_926], with each occurrence of the AE being counted 
(same subject can contribute multiple events to frequency).  Tabulations of in cidence and frequency will 
be performed separately for AEs overall and for related AEs only.  
Observed and change- from -baseline vital signs, laboratory, and ECG data  will be summarized  using the 
mean, median, standard deviation, minimum, and maximum . The m ost recent measurement prior to start 
of infusion of the first ZTI -01 dose will be regarded as baseline.  The number and percentage of subjects 
with laboratory, vital sign, and ECG abnormalities at baseline, subsequent visits, or early termination 
from the trial  will be tabulated. Th e results of all laboratory tests, physical exam  findings, ECG s, and vital 
signs will be presented in data listings.  
Pharmacokinetics : 
The pharmacokinetic outcome measures will be plasma and intrapulmonary PK of ZTI -01.  
The following plasma PK parameters will be derived from the plasma concentration v s. time curves for 
fosfomycin after ZTI -01 administration. Noncompartmental analysis will be used to determine PK 
parameters, but other modeling techniques can be employed as  needed. The below PK parameters will be 
estimated using Phoenix® WinNonlin® version 8.[ADDRESS_77760] and/or third dose s. 
• Maximum measured plasma concentration (C max) 
• Observed and extrapolated a rea under the concentration versus time curve (AUC 0-8; AUC 0-12; AUC 0-
inf) 
• Time to peak concentration (t max) 
• Terminal elimination half -life (t 1/2) 
• Terminal -phase elimination rate constant (λ z)  
• Volume of distribution (Vd)  
• Clearance (CL)  
PK parameters (C max, tmax,  and AUC 0-8) will be compared by [CONTACT_71506] C max and AUC 0-8. 
Intrapulmonary PK of ZTI -[ADDRESS_77761] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77762] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77763] 10, 2017  12. SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS 
DEPRU  will maintain appropriate medical and research records for this study, in compliance with Section 
4.9 of ICH E6 GCP, and regulatory and institutional requirements for the protection of confidentiality of 
subjects. As part of participating in a DMID -sponsored study, DEPRU  will permit authorized 
representatives of DMID and regulatory agencies to examine (and when required by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits and evaluation of the study 
safety and progress.  
Source data are all information, original records of clinical findings, observations, or other activities in a 
trial necessary for the reconstruction and evaluation of the trial. Examples of these original documents 
and data records include, but  are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory 
notes, memoranda, evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm or magnetic media, x- rays, and subject files and records 
kept at the pharmacies , laboratories, and medico- technical departments involved in the trial. 
DMID Protocol 16- [ADDRESS_77764] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77765] 10, 2017  13. QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, DEPRU  and its subcontractors are  
responsible for conducting routine quality assurance (QA) and quality control (QC) activities to internally 
monitor study progress and protocol compliance. The  Site PI  [INVESTIGATOR_71464] -related 
sites, source data/data collection forms, and reports for monitoring and auditing by [CONTACT_941] S ponsor, and 
inspection by [CONTACT_3482]. The Site PI  [INVESTIGATOR_71465] . 
The DCC will implement quality control procedures beginning with the data entry system and generate 
data quality control checks that will be run on the database. Any missing data or data anomalies will be communicated to DEPRU  for clarification and resolution. 
DMID Protocol 16- [ADDRESS_77766] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77767] 10, 2017  14. ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.1. Ethical Standard  
The Site PI  [INVESTIGATOR_71466] e trial is conducted in full conformity with principles of the Belmont 
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research of the 
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Re search 
(April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 and 56, and ICH E6; 62 Federal Regulations 
[ZIP_CODE] (1997), if applicable. The Site PI ’s institution will hold a current Federalwide Assurance (FWA) 
issued by [CONTACT_28820]  (OHRP) for federally -funded research.  
14.2. Institutional Review Board  
Before  enrollment of subjects into th e trial, the protocol and ICF will be reviewed and approved by [CONTACT_71507].  
The responsible official for the IRB will sign the IRB letter of protocol approval before  the start of th e 
trial and provide a copy and the  IRB FWA number to DMID.  
If amendments to the protocol are  required, the y will be written by [CONTACT_941] S ponsor and provided to the Site 
PI [INVESTIGATOR_71467]. 
14.3. Informed  Consent Process  
The Site PI  [INVESTIGATOR_71468] 5.1. Before 
any study procedures are performed, subjects must sign an ICF that complies with the requirements of [ADDRESS_77768] ’s trial participation. Before any study procedures are performed, 
including pre -screening of subjects for eligibility, subjects will receive a comprehensive explanation of 
the proposed study procedures and study drug . This will include the nature, risks , and possible benefits of 
the trial, alternate therapi[INVESTIGATOR_014], any known AEs, the investigational status of the study drug , and other 
elements that  are part of obtaining proper informed consent. Subjects will also receive a detailed 
explanation of the proposed use and disclosure of their protected health information, including 
specifically their blood, urine, and BAL  samples. Subjects will be allowed  sufficient time to consider 
participation in th e trial, after having the nature, risks, and possible benefits of the  trial explained to them, 
DMID Protocol 16- [ADDRESS_77769] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77770]’s 
risk of receiving the study drug . This new informati on will be communicated by [CONTACT_7910]  [INVESTIGATOR_71469]. The ICF will be updated and 
subjects will be re- consented per IRB requirements, if necessary. Subjects will be given a copy of all ICFs 
that they sign.  
14.4. Exclusion of Women, Minorities, and Children (Special Populations)  
The trial will enroll  all s ubjects aged [ADDRESS_77771] Inclusion Criteria (see 
Section 5.1.1) and do not meet any of the Subject Exclusion Criteria (see Section 5.1.2), regardless of 
religion, sex, race, or ethnic ity.  Persons younger than [ADDRESS_77772] 
party without prior written approval of the Sponsor. 
All information provided by [CONTACT_941] S ponsor and all data and information generated by [CONTACT_71508] e 
trial (other than a subject’s medical records) wi ll be kept confidential by [CONTACT_7910]  [INVESTIGATOR_71470] 16- [ADDRESS_77773] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77774] 10, 2017  personnel to the extent permitted by [CONTACT_2371]. This information and data will not be use d by [CONTACT_7910]  [INVESTIGATOR_71471]. These restrictions do not apply to: 
(1) information which becomes publicly available through no fault of the Site PI  [INVESTIGATOR_29355]; 
(2) information which is necessary to disclose in confidence to an IRB solely for evaluation of th e trial; 
(3) information which is necessary to disclose in order to provide appropriate medical care to a subject; or 
(4) study results which may be published as described in Secti on 16.  
The study monitor, applicable regulatory authorities  (e.g. , FDA) , or other authorized representatives of 
the S ponsor may inspect all documents and records required to be maintained by [CONTACT_7910] . This 
includes, but is not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the 
subjects in th e trial. DEPRU  will permit access to such records.  
To protect privacy, we have received a Certificate of Confidentiality. With this Certificate, the researchers 
cannot be forced to release information that may identify the research subject, even by a court subpoena, 
in any federal, state, or local  civil, criminal, administrative, legislative, or other proceedings. The 
researchers will use the Certificate to resist any demands for information  that would identify the subject, 
except as explained below.  
The Certificate cannot be used to resist a deman d for information from personnel of the [LOCATION_002] 
Government that is used for auditing or evaluation of federally funded projects, like this  study, or for 
information that must be released in order to meet the requirements of the Federal Food and Drug 
Administration (FDA).  
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing information about 
themselves or their involvement in this research. If any person or agency  obtains a written consent to 
receive research information, then the researchers may not use the Certificate to withhold that 
information.  
The Certificate of Confidentiality does not prevent the researchers from reporting without the subject’s 
consent, information that would identify the subject as a partici pant in the research project regarding 
matters that must be legally reported including: child and elder abuse, sexual abuse, or wanting to harm 
themselves or others.  
14.6. Study Discontinuation  
If the trial is discontinued, subjec ts who have signed the ICF  and a re administered study drug , will 
continue to be followed for safety for the duration of the scheduled  follow -up period. No further study 
drug will be administered.  
14.7. Costs, Subject Compensation, and Research Related Injuries  
There is no cost to subjects for the research tests, procedures, and study drug while taking part in th e trial. 
Procedures and treatment for clinical care may be billed to the subject, subject’s insurance, or third party. 
DMID Protocol 16- [ADDRESS_77775] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77776] 10, 2017  Subjects may be compensated for thei r participation in the trial. Compensation will be in accordance with 
the local IRB’s policies and procedures, and subject to IRB approval.  
14.8. Future Use of Stored Specimens  and Data 
Aside from plasma or BAL sample reanalysis, no future use of specimens i s intended with this protocol. 
Plasma and BAL samples will be stored at –20 to – 70°C for up to [ADDRESS_77777] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77778] enrolled in th e trial. All data collection forms will be completed in a neat, legible 
manner to ensure accurate interpretation of data. Black or blue ink is required to ensure clarity of 
reproduced copi[INVESTIGATOR_014]. When making a change or correction, cross out the original entry with a single line 
and initial and date the ch ange. Do not erase, overwrite, or use correction fluid or tape on the original.  
Data reported in the  eCRF  derived from the data collection forms should be consistent with the data 
collection forms or the discrepancies should be explained.  
The S ponsor  or de signee will provide guidance to the Site PI  [INVESTIGATOR_71472] . 
15.1. Data Management Responsibilities  
All data collection forms and laboratory reports will  be reviewed by [CONTACT_71509], who will ensure that they are accurate and complete. AEs will be recorded on the appropriate 
data collection form, assessed for severity and re lationship, and reviewed by [CONTACT_7910]  [INVESTIGATOR_71473]-investigator.  
Data collection is the responsibility of the study personnel at DEPRU  under the supervision of the Site PI . 
During th e trial, the Site PI [INVESTIGATOR_71474]. 
The DCC for th e trial will be responsible for data management, quality review, analysis, and reporting. 
15.2. Data Capture Methods 
Clinical (including, but not limited to, AE/SAEs, concomitant medications, medical history, physical assessment s, and clinical laboratory values), will be entered into a [ADDRESS_77779] protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the data collection forms completed by [CONTACT_71510].  
15.3. Types of Data  
A variety of data will be collected and used in the aforementioned  analysis. These data inc lude, but are 
not limited to demographic s, medical history and prior m edication s, hematology, c oagulation, urinalysis 
and blood c hemistry, v ital signs, ECGs , and PK  blood and BAL samples  (Appendix A ). 
DMID Protocol 16- [ADDRESS_77780] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77781] 10, 2017  15.4. Timing/Reports  
As the duration of the trial  is short, an initial review of data is anticipated for QC purposes. All data will 
be thoroughly reviewed upon completion before  analysis and writing of the study report.  
15.5. Study Records Retention  
DEPRU  will maintain appropriate medical and research records for th e trial, in compliance with ICH E6 
R1, Section 4.9, regulatory and institutional requirements for the protection of confidentiality of subjects. 
DEPRU  will permit authorized representatives of the Sponsor, D MID , and regulatory agencies to 
examine (and when required by [CONTACT_1289], copy) clinical records for the purposes of clinical site 
monitoring, quality assurance reviews, audits, and evaluation of the study safety and progress. A Site Master File will b e maintained to include essential documents.     
Study documents will be retained for a t least  [ADDRESS_77782], the Site PI , or DEPRU  
personnel. If  deviations  occur , corrective actions will  be promptly developed and implemented by 
[CONTACT_71492] . 
These practices are consistent with ICH E6:  
4.[ADDRESS_77783]'s chart. Protocol deviations will be sent to the local  IRB/IEC per their guidelines. The 
Site PI  [INVESTIGATOR_71475] l are responsible for knowing and adhering to their IRB requirements. 
DMID Protocol 16- [ADDRESS_77784] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77785] submitted for them  to the National Library of 
Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an electronic version of their final, peer -
reviewed manuscripts upon acceptance for publication, to be made publicly available no later than [ADDRESS_77786] be accessible to the public on PubMed Central no later than 12 months after publication.  
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/  
• NIH Office of Extramural Research (OER) Grants and Funding, http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical trials supported by [CONTACT_71511].gov, no later than [ADDRESS_77787] applied for certification of 
delayed posting. 
As part of the result posting a copy of this protocol (and its amendments) and a copy of the Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this trial the Investigators will register the trial and post results.   
The responsible party does not plan to request certification of delayed posting. 
Refer to:  
• Public Law 110- 85, Section 801, Clinical Trial Databases  
• 42CFR11 
• NIH NOT -OD-16-[ADDRESS_77788] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77789] KPC -2-producing  Klebsiella pneumoniaei .  Antimicrob Agents Che mother  
2016;60:4128–39.  
Alemayehu D, Quinn J, Cook J, Kunkel M and Knirsch CA. A Paradigm Shift in Drug Development for 
Treatment of Rare Multidrug Resistant Gram -Negative Pathogens. Clin Infect Dis 2012 Aug;55(4):562-
567. 
Al-Hasan MN, Eckel -Passow JE, Bad dour LM. Bacteremia Complicating Gram -Negative Urinary Tract 
Infections: A Population -Based Study. J Infect. 2010 April ; 60(4): 278–285.  
Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL.     Pharmacokinetics- pharmacodynamics of antimicrobial therapy: It’s not just for mice anymore. Clin Infect 
Dis 2007; 44:79- 86. 
Ambrose PG, Bhavnani SM, Ellis -Grosse EJ, Drusano GL.     Pharmacokinetics-  pharmacodynamics 
considerations in the design of hospi[INVESTIGATOR_307] -acquired or ventilator -associated bacterial pneumonia studies: 
look before you leap! Clin Infect Dis  2010; 51(Suppl 1):S103- S110. 
Asuphon O, Montakantikul P, Houngsaitong J, Kirati sin P, Sonthisombat P.  Optimizing intravenous 
fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamics (PK/PD) simulations.  Int J Infect Dis 2016;50:23- 9. 
Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis  Suppl 1990 ; 
74:63– 70. 
Dinh A, Salomon J, Bru JP Bernard L. Fosfomycin: efficacy against infections caused by [CONTACT_71512]-resistant bacteria. Scand J Inf ect Dis.  2012;44(3):182- 189. 
Drusano G. Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents. Clin Infect 
Dis 2003; 36(Suppl 1):S42 –50. 
Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, and Rice LB. In vitro activity of fosfom ycin 
against blaKPC -containing Klebsiella pneumoniae isolates, including those non- susceptible to tigecycline 
and/or colistin. Antimicrob Agents Chemother  2010;54:526–529.  
Edwards JR, Peterson KD, Banerjee S, Allen -Bridson K, Morrell G, Dudeck MA, Pollock DA, and Horan 
TC. National Healthcare Safety Network (NHSN) report: Data summary for [ADDRESS_77790] Control  2009;37:783- 805. 
Falagas ME, Konstatina PG, Kokolakis GN and Rafilidis PI. Fosfomycin: Use Beyond Urinary Tra ct and 
Gastrointestinal Infections . Clin Infect Dis  2008;46(7):1069- 1077. 
DMID Protocol 16- [ADDRESS_77791] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77792] 10, 2017  Falagas ME, Vouloumanou EK, Toglas AG, Karadima M, Kapaskelis AM, Rafailidis P, and Athanasiou 
S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta- analysis o f randomized 
controlled trials. J Antimicrob Chemother  2010;65:1862–1877  
Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug -resistant, including extended -spectrum Beta - lactamase producing, Enterobacteria ceae 
infections: a systematic review. Lancet Infect Dis  2010b;10:43–50.  
Florent A, Chinchmanian RM, Cua E and Pulcini C. Adverse events associated with intravenous fosfomycin. Intl J Antimicrobial Agents  2011; 37:82–[ADDRESS_77793] infections in older adults residing in long -term care facilities. Annals of 
Long-Term Care: Clinical Care and Aging. 2012;20(4):33- 38.  
Granowitz  E, Brown  R. Antibiotic Adverse Reactions and Drug Interactions. Critical Care Clinics.  
2008;24(2). 
Kanj SS and Kanafani ZA. Current Concepts in Antimicrobial Therapy Against Resistant Gram -Negative 
Organisms: Extended- Spectrum β -Lactamase–Producing Enterobacteriaceae, Carbapenem -Resistant 
Enterobacteriaceae, and Multidrug- Resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250-
259. 
Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). 
Ann N Y Acad Sci  1974;235:364–386.  
Karageorgopoulos DE, Wang R, Xu- hong Y, and Falagas ME. Fosfomycin: evaluation of the published 
evidence on the emergence o f antimicrobial resistance in Gram -negative pathogens. J Antimicrob 
Chemother  2012;67:255– 268. 
Kasotris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, and Falagas ME.  Synergy of fosfomycin with other antibiotics for Gram -positive and Gram Negative Bacteri a. Eur J Clin Pharmacol . 
2010;66:359- 368. 
Kawabata T, Yokota M, Mayama T and Shimizu K. A post -marketing surveillance study of fosfomycin 
sodium for injection: A nationwide prospective study of safety in 100,000 cases. Translated from Jap J Chemo . 2000;48( 11):851- 874. 
Koeijers JJ, Verbon A, Kessels AGH, Bartelds A, Donker G, Nys S, Stobberingh EE. Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility. Urology : 2010, 
76(2), 336- 340. 
Koeda T, Odaki M, Sasaki H, Yokota M, Watanabe H, Kawaoto H, Ito T, Ishiwatari N. Toxicological 
studies on fosfomycin -Na salt. I. Acute toxicity in mice and rats (author’s transl). Jpn J Antibiot  1979 
Jan;32(1):[ADDRESS_77794] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77795] 10, 2017  Koeda T, Odaki M, Sasaki H, Yokota M, Niizato T, Watanabe H, Kawao to H, Ito T, Kumagai K, 
Ishiwatari N. and Suzuki H. Toxicological studies on fosfomycin -Na salt. II. Subscute toxicity in rats and 
rabbits (author’s transl). Jpn J Antibiot  1979b Jan;32(1):67- 81. 
Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA and Cardo DM. Estimating 
Health Care- Associated Infections and Deaths in  U.S. Hospi[INVESTIGATOR_600], 2002. Public Health Reports . March –
April 2007;122:160- 166. 
Lepak AJ, Zhao M, Vanscoy B, Taylor DS, Ellis -Grosse E, Ambrose PG, and Andes DR. In vivo 
Pharmacok inetics and Pharmacodynamics of ZTI -01 (Fosfomycin for Injection) in the Neutropenic 
Murine Thigh Infection Model against E. coli, K. pneumoniae, and P. aeruginosa.  Antimicrob. Agents 
Chemother . AAC.[ZIP_CODE]- 17; Accepted manuscript posted online 10 April 2017  
Magiorakos AP, Suetens C, Monnet DL, Gagliotti C, Heuer OE, and EARS -Net Coordination Group and 
EARS -Net Participants. The rise of carbapenem resistance in Europe: just the tip of the iceberg? 
Antimicrobial Resistance and Infection Control  2013, 2:6.  
Matzi V, Lindenmann J, Porubsky C, Kugler SA, Maier A, Dittrich P, et al. Extracellular concentrations 
of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010; 65:995–8.  
Mazzuli T. Diagnosis and management of simple and complicated urinar y tract infections (UTIs). Can J 
Urol 2012;19(Suppl 1):42- 48. 
Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, and Falagas ME. Intravenous 
fosfomycin for the treatment of nosocomial infections due to carbapenem -resistant Klebsiella pneu moniae 
in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010;16:184–186.  
Michalopoulos A, Lividitis IG, and Gougoutas V. Review:  The revival of fosfomycin. International 
Journal of Infectious Diseases. 2011;15: e732– e739  
Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin for multiresistant 
pseudomonas aeruginosa in cystic fibrosis. Journal of Cystic Fibrosis 2 (2003) 19 –24.  
Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, and Andersson DI. Biologi cal costs and mechanisms of 
fosfomycin resistance in Escherichia coli . Antimicrob Agents Chemother  2003;47;2850- 2858. 
Popovic M, Steinort D, Pi[INVESTIGATOR_24124] S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol 
Infect Dis 2010;29:127–142.  
Pulcini C,  Bush K, Craig WA, Frimody- Meller N, Grayson ML, Mouton JW, Turnidge J, Harbarth S, 
Gyssens IC and ESCMID Study Group for Antibiotic Policies. Forgotten Antibiotics: An Inventory in 
Europe, the [LOCATION_002], Canada, and Australia.  Clin infect Dis  2012;54(2):268 –274  
Rodvold KA, George JM, and Yoo L. Penetration of anti -infective agents into epi[INVESTIGATOR_71444]: 
focus on antibacterial agents. Clin Pharmacokinet  2011;50:637–664.  
DMID Protocol 16- [ADDRESS_77796] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77797] 10, 2017  Roussos N, Karageorgopoulos DE, Samonis G, and Falagas ME. Clinical signifi cance of the 
pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with 
systemic infections. J Antimicrob Agents 2009;34:506 –515.  
Waiwarawooth J. Combination Treatment of Pi[INVESTIGATOR_049]/Tazobactam, Amikacin and Fosf omycin for 
Probable Multidrug - Resistant Pseudomonas aeruginosa Infection:  A Case Report. J Infect Dis 
Antimicrob Agents 2004;21:89- 91. 
VanScoy BD, McCauley J, Ellis- Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Amborse PG.  
Exploration of the pharmacoki netic -pharmacodynamic relationships for fosfomycin efficacy using an in 
vitro  infection model.  Antimicrob Agents Chemother  2015;59:7170–7.  
VanScoy BD, McCauley J, Bhavnani SM, Ellis- Grosse EJ, Amborse PG.  Relationship between 
fosfomycin exposure and ampl ification of  Escherichia coli  subpopulations with reduced susceptibility in 
a hollow -fiber infection model.  Antimicrob Agents Chemother  2016;60:5141 –5. 
Wenzler E, Ellis -Grosse EJ, Rodvold KA. Pharmacokinetics, safety, and tolerability of single- dose 
intravenous (ZTI -01) and oral fosfomycin in healthy volunteers. Antimicrob Agents Chemother 
2017;61:e00775- 17. 
 
DMID Protocol 16- [ADDRESS_77798] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77799] 10, 2017  18. SUPPLEMENTS /APPENDICES  
APPENDIX A: SCHEDULE OF STUDY PROCEDURES AND 
EV ALUATIONS  
Table 9: Schedule of study procedures and evaluations  
 
 
Activities  
Screening  
Visit 
Baseline  
Visit 
Treatment 
Phase  
Discharge 
Visit 
Telephone  
Follow -Up 
Early Termination  
Unscheduled Visit  
Day  
-30 to -1 Day  
-1 to 1 Days  
1 to 2  Day 2  Day 3  
Informed Consent  X       
Review Eligibility Criteria  X X      
Randomization   X      
Demographics  X       
Admission to DEPRU   X      
Medical History  X Xa      
Counsel on Birth Control  X   X  X  
Counsel on non- prescription 
medications  X       
Prior/Concomitant Medication 
Review  X X X X X X X 
Collect and Record AEs /SAEsb   X X X X X 
Height / BMI  X     X  
Vital Signsc X X X X  X X 
Physical Exam (including weight)  X X  X  X Xd 
DMID Protocol 16- [ADDRESS_77800] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77801] 10, 2017  Alcohol and Tobacco Historye X       
ECG (12 -lead)f X X X    X 
HIV Antibody, Hepatitis B Ag, 
Hepatitis C Antibody  X       
Hem -Coag -UAg X  X X  X  
Chemistryg X X X X  X  
Lipi[INVESTIGATOR_805], LDHg X  X X  X  
Pregnancy Testsh X X      
Urine & Breath Tox Screensi  X X      
SARS -CoV - 2 (COVID -19) Testj  X X      
Place Two Peripheral IVs   X      
Study Drug Administrationk   X     
Blood for Urea Assayl   X     
Blood PK Samplesm   X     
Bronchoscopy and BALn   X     
Discharge from DEPRU     X    
a Update medical history as appropriate since screening  including non- pharmacologic 
treatments/procedures within [ADDRESS_77802] AEs  and SAEs  from the time the start of treatment (Day 1)  through Day 3.  
c Vital signs (heart rate, blood pressure, temperature, respi[INVESTIGATOR_697], and peripheral oxygen saturation), 
measured with subject in the supi[INVESTIGATOR_1662] -recumbent position, will be obtained at the following 
timepoints: Screening, Baseline ( Day -1), immediately prior (within 10 minutes) to each of three doses of 
Study Drug, at approximately 0.5, 1, 2, and 5 hours (each ± 10 minutes) as after the  start of infusion for 
each dose , and before  discharge from DEPRU . If vital sign s are abnormal, repeated readings  will be 
obtained up to twice more,  5 to 10 minutes apart . If they remain abnormal, unscheduled vital signs will be 
repeatedly obtained until they normalize (at investigator’s discretion). Since changes in vital signs are expected during bronchoscopy, when a vital sign timepoint is scheduled during a subject’s bronchoscopy, 
that time point will be measured immediately before  the start of bronchoscopy. 
d At unscheduled visits, weight may be performed as part of the physical exam but is not required  
DMID Protocol 16- [ADDRESS_77803] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77804] 6 months , lifetime tobacco history  
f ECGs will be performed in the supi[INVESTIGATOR_1662] -recumbent position (after rest for at least 10 min) at 3 
timepoints: at Screening, Day 1 ( before  first dose of Study Drug), and within 1- [ADDRESS_77805] dose 
(3rd dose) of study drug. In case of premature di scontinuation of study drug, ECG is to be performed 
before  discharge. 
g  At Screening , and before  discharge (Day 2), obtain hematology labs  (white blood cell count, 
hemoglobin, hematocrit, and platelet count, neutrophils, lymphocytes, monocytes, eosinophils, 
basophils); coagulation tests (aPTT and PT) , chemistry labs (albumin, glucose, blood urea nitrogen 
(BUN), potassium, magnesium, calcium, sodium, phosphorus, total protein, creatinine, triglycerides, 
total cholesterol, CPK, phosphorus, AST, ALT, total bilirubin, direct bilirubin, ALP, LDH), and 
urinalysis  (leukocyte esterase, blood, glucose, protein, pH, and specific gravity  via dipstick with 
addition of urine microscopy if dipstick abnormal ). At Baseline (Day -1 to Day 1 ) obtain albumin, 
glucose, BUN, potassium, magnesium, calcium, sodium, phosphorus, total protein, creatinine, CPK, 
AST, ALT, total bilirubin, and ALP. Approximately two hour s prior to bronchoscopy (Day 2) obtain 
sodium, potassium, magnesium, calc ium, and phosphorus.  
h  Serum pregnancy test for  women of childbearing potential at screening, and urine pregnancy test for 
women of childbearing potential at Baseline (Day - 1 to Day 1)  
i  Alcohol Breathalyzer test, Urine cotinine, and Urine drug screen at Screening and Baseline (Day -1 to 
Day 1/ admission to DEPRU ). Cotinine will be reported qualitatively as positive/negative.  Urine drug 
screen will consist of: barbiturates, benzodiazepi[INVESTIGATOR_1651], THC, cocaine, opi[INVESTIGATOR_858], and 
amphetamine /methamphetamine .  
j.   Test for SARS -CoV -2 (COVID -19) at Screening  or Baseline (Day -1 to Day 1) within 72 hours of 
admission  
k Subjects will receive a total of three doses of ZTI -01 (fosfomycin disodium) 6g, administered every 8 
hours, as 1- hour intravenous infusion (+10 minute window)  
l Blood sample to determine plasma urea concentration will be obtained just before  or during the 
scheduled bronchoscopy  
m  PK blood samples will be collected at 15 timepoints: before (within 10 minutes) the first, second, and 
third doses of study drug, at 30 minutes (during infusion), 1 hour (within 5 minutes after the end of infusion), [ADDRESS_77806] dose of ZTI -01, and at 30 
minutes (during infusion), 1 hour (within 5 minutes after the end of infusion ), [ADDRESS_77807] (last) infusion of ZTI -01. Blood PK samples will  be 
drawn for all subjects w ithin the following windows: - 1 to - 10 minutes for scheduled samples at pre-
dose; +/ - 5 minutes for scheduled samples at 30 minutes , 1 hour 15 minutes, and 2 hours; +0-[ADDRESS_77808] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77809] 10, 2017  after end of infusion for the scheduled sample at 1 hour; +/ - 15 minutes for scheduled samples at 5,  8, 
and 12 hours. Actual times for dosing and sample will  be recorded.  
n Bronchos copy with BAL at 30 minutes (during the 1- hr infusion), 1 hr 15 minutes, 2, 5, or 8 hours from 
T0 (defined as the start time of the last [third] infusion of ZTI -01). BAL PK samples will  be obtained 
within +/-  15 minutes of scheduled timepoint. Actual times  for dosing and sample will  be recorded.  
APPENDIX B: ADVERSE EVENT TOXI CITY GRADING SCALE  
ABBREVIATIONS :  Abbreviations utilized in the Table:  
 
ULN = Upper Limit of Normal              LLN = Lower Limit of Normal  
Rx = Therapy                                       Req = Required  
Mod = Moderate                                  IV = Intravenous  
ADL = Activities of Daily Living            Dec = Decreased  
 
ESTIMATING SEVERITY GRADE  
 
For abnormalities NOT found elsewhere i n the Toxicity Tables use the scale below to estimate grade of 
severity:  
 
GRADE [ADDRESS_77810]’s daily activities.  
GRADE [ADDRESS_77811]’s usual daily activity and may require systemic drug therapy or other treatment.  Severe events are usually 
incapacitating.  
 
SERIOUS OR LIFE -THREATENING AEs  
DMID Protocol 16- [ADDRESS_77812] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77813] 10, 2017   
ANY clinical event that meets the SAE criter ia, is considered a grade 3 event. (examples of clinical 
events considered to be life -threatening include, but are not limited to:  seizures, coma, tetany, diabetic 
ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute p sychosis, severe 
depression).  
COMMENTS REGARDING THE USE OF THESE TABLES 
• Standardized and commonly used toxicity tables (Division of AIDS, National Cancer Institute 
[NCI] Common Toxicity Criteria [CTC], and World Health Organization [WHO]) have been 
adapte d for use by [CONTACT_71513] (DMID) and modified to 
better meet the needs of participants in DMID trials.  
• For parameters not included in the following Toxicity Tables, DEPRU  should refer to the “Guide 
for Estimating Sev erity Grade” located above.  
• Criteria are generally grouped by [CONTACT_6764].  
• Some protocols may have additional protocol specific grading criteria, which will supersede the 
use of these tables for specified criteria.  
 
Table 10: Clinical adverse event definit ion and grading scale  
Clinical Adverse Events      
VITAL SIGNS  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)   
Fever (°C) * 38.0 – 38.4 38.5 – 38.9 ≥39.0 * Oral 
temperature; no recent hot or 
cold beverages 
or smoking.   
             (°F) * 100.4 – 101.1  101.2 – 102.0  ≥102.1   
Tachycardia - beats per 
minute  101 – 115 and 
>25% change from baseline  116 – 130 and 
>25% change from baseline  > 130 or 
ventricular dysrhythmias  and 
>25% change 
from baseline   
DMID Protocol 16- [ADDRESS_77814] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77815] 10, 2017  Bradycardia - beats per 
minute  50 – 54  or 45 - 
49 bpm if 
baseline <[ADDRESS_77816] is 
asymptomatic; no 
treatment 
required  45 – 49 or 40 -
44 if baseline 
<[ADDRESS_77817] is 
asympt omatic; 
no treatment 
required; Site  
PI/sub -
investigator may 
confirm with 
ECG or 12- lead 
Holter monitors 
to rule out 
arrhythmia or 
advanced heart 
block.  < 45 or  <40 bpm 
if baseline <[ADDRESS_77818] is 
symptoma tic 
and/or requires treatment; S ite 
PI/sub -
investigator 
should confirm 
with ECG or 12-
lead Holter 
monitors to rule 
out arrhythmia or 
advanced heart 
block   
 Hypertension (systolic) - mm 
Hg 141-150 151-160 > [ADDRESS_77819] 
conditions, not 
sleepi[INVESTIGATOR_71476].  
Hypertension (diastolic) - mm 
Hg 91-95 96-100 > 100   
Hypotension (systolic) - mm 
Hg 85-89 80-84 < 80  
Tachypnea – breaths per 
minute  
 
 
  23-25 26-30 >[ADDRESS_77820] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77821] 10, 2017  Hemorrhage, Blood Loss  Estimated blood 
loss < 100 mL  Estimated blood 
loss > 100 mL, 
no transfusion  
required  Transfusion 
required   
QTc interval (prolonged)  QTc 45 0-480 
msec 
 QTc 4 81-500 
msec  QTc >5 00 msec  
  
PR Interval (prolonged)  PR 200- 250 msec 
and >25% change 
from baseline  PR >250 msec 
and >25% 
change from 
baseline  AV block 2nd 
degree Type II or 
higher OR 
ventricular pause 
>3 sec   
QRS Interval (prolonged)  QRS 120- 150 
msec and >25% 
change from 
baseline  QRS 150- 180 
msec and >25% change from 
basel ine New bundle 
branch block   
RESPI[INVESTIGATOR_71477] 1   Grade 2   Grade 3   
Cough  Transient - no 
treatment  Persistent cough;  Interferes with 
daily activities   
Bronchospasm, Acute  Transient; no 
treatment; 71% - 
80% FEV1 of 
peak flow  Requires 
treatment; 
normalizes with 
bronchodilator; 
FEV1 60% -  
70% (of peak 
flow)  No normalization 
with bronchodilator; 
FEV1 <60% of 
peak flow   
Dyspnea   Does not 
interfere with usual and social 
activities  Interferes with 
usual and social 
activities, no 
treatment  Prevents daily 
and usual social 
activity or 
requires 
treatment   
GASTROINTESTINAL    Grade [ADDRESS_77822] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77823] 10, 2017  Vomiting  No interference 
with activity or 1 
- 2 epi[INVESTIGATOR_1841]/24 
hours  Some 
interference with activity or > 2 
epi[INVESTIGATOR_1841]/24 
hours  Prevents daily 
activity or 
requires IV 
hydration  
Diarrhea  2 - 3 loose or 
watery stools or < 400 gm/24 
hours  4 - 5 loose or 
watery stools or 400 -  800 gm/24 
hours  6 or more loose 
or watery stools or > 800gms/24 
hours or requires 
IV hydration   
REACTOGENICITY        
LOCAL REACTIONS   Grade 1   Grade 2   Grade 3   
Pain Does not 
interfere with 
activity  Repeated use of 
non-narcotic 
pain reliever > 
[ADDRESS_77824]   
Erythema/Redness **  2.5 - 5 cm  5.1 - 10 cm  > 10 cm  ** In addition to 
grading the 
measured local 
reaction at the 
greatest single 
diameter, the 
measurement 
should be 
recorded as a 
continuous 
variable.  
Induration/Swelling ***  2.5 - 5 cm and 
does not interfere 
with activity  5.1 - 10 cm or 
interferes with 
activity  > 10 cm or 
prevents daily activity  ***Induration/S
welling should be evaluated and 
graded using the 
functional scale 
as well as the 
DMID Protocol 16- [ADDRESS_77825] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77826] 10, 2017  actual 
measurement  
SYSTEMIC  Grade 1   Grade 2  Grade 3   
Allergic Reaction   pruritus without 
rash   localized 
urticaria   generalized 
urticaria; 
angioedema or 
anaphylaxis   
Headache  No interference 
with activity  Repeated use of 
non-narcotic 
pain reliever > 
24 hours or 
some 
interference with 
activity  Significant; any 
use of narcotic 
pain reliever or 
prevents daily 
activity   
Fatigue  No interference 
with activity  Some 
interference with 
activity  Significant; 
prevents daily 
activity   
Myalgia  No interference 
with activity  Some 
interference with 
activity  Significant; 
prevents daily 
activity   
ALL OTHER CONDITIONS  Grade 1  Grade 2  Grade 3   
Illness or clinical adverse 
event (as defined according to applicable regulations)  No interference 
with activity  Some 
interference with 
activity not 
requiring 
medical 
intervention  Prevents daily 
activity and 
requires medical 
intervention   
 
  
DMID Protocol 16- [ADDRESS_77827] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77828] 10, 2017   
Table 11: Laboratory adverse event definition and grading scale  
LABORATORY ADVERSE EVENTS        
BLOOD, SERUM, PLASMA  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Sodium – Hyponatremia mEq/L  132 – <LLN  130 – <132 <130  
Sodium – Hypernatremia mEq/L  >ULN – 148 >148 – 150  >150  
Potassium – Hyperkalemia mEq/L  >ULN – 5.2 >5.2 - 5.4 >5.4 
Potassium – Hypokalemia mEq/L  3.1-<LLN  3.0-<3.1 <3.0 
Glucose – Hypoglycemia mg/dL  65 - 69 55 - <65 <55 
Glucose – Hyperglycemia  
Fasting – mg/dL  >ULN - 120 >120 - 130 >130  
Glucose – Hyperglycemia  
Random – mg/dL  141 - 159 >159 – 200 >200  
Blood Urea Nitrogen mg/dL  21-26 >26 – 31 > 31 
Creatinine – mg/dL  >ULN – 1.7 >1.7 – 2.0 >2.0 
Calcium – hypocalcemia mg/dL  8.0 – <LLN  7.5 – <8.0 <7.5 
Calcium – hypercalcemia mg/dL  >ULN – 11.0 >11.0 – 11.5 >11.5  
Magnesium – hypomagnesemia mg/dL  1.3 – 1.7 1.1 – <1.3 <1.1 
Phosphorous – hypophosphatemia 
mg/dL  2.1 – 2.2 1.9 – <2.1 <1.9 
CPK – mg/dL  221-1000  >1000-1500  >1500  
Albumin – Hypoalbuminemia g/dL  2.8 – 3.4 2.5 – <2.8 < 2.5  
Total Protein – Hypoproteinemia g/dL  5.2 – <LLN  5.0 – <5.2 < 5.0  
Alkaline phosphatase (ALP) – U/L 111 - 240 >240– 360 >[ADDRESS_77829] U/L  42 – 105 >105-175 >175  
ALT U/L (Female)  >ULN  - 105 >105-175 >175  
ALT U/L (Male)  >ULN  – 105 >105-175 >175  
Bilirubin (serum total) - mg/dL  1.6 - 2.5 >2.5 - 3.0 > 3.[ADDRESS_77830] bilirubin – mg/dL  0.7-2.0 >2.0-3.5 >3.5 
Total cholesterol – mg/dL  301 – 400 >400 -500 >500 
Triglycerides – mg/dL  >500 – 750 >750 – 1000  >1000  
Lactate dehydrogenase – U/L  >200 -500 >500 -800 >800  
Hemoglobin (Female) - g/dL  11.0 – 11.9 9.5 – <11.0 < 9.[ADDRESS_77831] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77832] 10, 2017  Hemoglobin (Male) - g/dL  12.0 – 13.6 10.0 – <12.0 <10.0  
WBC Increase - cell/mm3  9900 – 15,000  >15,00 0 – 20,000  > 20,000  
WBC Decrease - cell/mm3  2,500 – 3100 1,500 – <2,500 < 1500  
Lymphocytes Decrease - cell/mm3  500 – <600 400 – <500 < 400 
Neutrophils Decrease - cell/mm3  1,500 - < 2000  1000 - <1500  < 1000  
Eosinophils - cell/mm3  > 700 - 750 >750 - 1500  > 1500  
Platelets Decreased - cell/mm3  120,000 – < 149,000  100,000 – <120,000  <100,000  
PT – seconds (prothrombin time)  > ULN – 14.4 >14.4 – 15.7 > 15.7  
aPTT – seconds (activated partial 
thromboplastin time)  > ULN – 42.1 >42.1 – 50.0 > 50.0  
URINE   Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Protein  1+ 2+ >2+ 
Glucose  1+ 2+ >2+ 
Blood (microscopic) - red blood cells per 
high power field (rbc/hpf)  5-10* >10-50*  > 50 and/or 
gross 
blood*  
* Isolated presence of blood in urinalysis is acceptable for menstruating females.  
  
DMID Protocol 16- [ADDRESS_77833] 2020  
 ________________________________________________________________________________________________________  
 
DMID/NIAID/NIH           [ADDRESS_77834] 10, 2017  APPENDIX C: V ENIPUNCTURE SCHEDULE  AND VOLUMES  
Table 12: Venipuncture schedule and volumes  
 
Scheduled Laboratory 
Assessments  Study Days  Blood 
Volume 
per 
Sample 
(mL)  Total 
Number of 
Samples Total 
Blood 
Volume 
(mL)  
Screening  
(Day -30 to 
Day -1) 
 Baseline 
(Day -1 to 
Day 1)  Treatment 
and 
Discharge 
(Days 1 -2)    
Chemistry  X X X 9 3 27 
Electrolytes (only)    X 4.5 1 4.5 
Hematology X  X 4 2 8 
Coagulation  X  X 2.7 2 5.4 
Serum Pregnancy   X   5 1 5 
Serologya X   8.5 1 8.5 
Urea Blood Sample    X 4 1 4 
PK Blood Samples    X 4 15 60 
Total blood volume 
(mL)b 29.[ADDRESS_77835];  blood volume per study  phase  is 
reflected at the bottom of each column.  